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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in North 
America. The highest risk factor for PDAC is recurrent pancreatitis. While the link between 
PDAC and pancreatitis is unknown, de-differentiation of acinar cells is common to both 
diseases. Our lab has shown that Activating Transcription Factor 3 (ATF3), a factor 
upregulated during pancreatic injury, contributes to the development of acinar-to-ductal cell 
metaplasia (ADM), a precursor phenotype of PDAC. The goal of this study was to identify 
how ATF3 contributes to ADM. I hypothesize that ATF3 regulates acinar gene expression 
promoting ADM. We observed decreased ADM development in Atf3-/- acinar cultures, along 
with expression changes in differentiation genes and ADM promoting pathways (EGFR) in 
vivo. Assessment following chronic injury indicated absence of ATF3 resulted in decreased 
tissue damage. These results suggest a novel mechanism where ATF3 promotes ADM 
through loss of the mature acinar cell phenotype.  
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Chapter 1  
1 Introduction 
1.1 Overview 
Pancreatitis is a debilitating disease defined by inflammation and fibrosis of the exocrine 
pancreas (Roberts, 2015). Patients diagnosed with pancreatitis are 20 to 60 times more 
likely to develop pancreatic ductal adenocarcinoma (PDAC), which has a 6-7% survival 
rate 5 years post-diagnosis (Yadav & Lowenfels, 2013). The factors that link these 
diseases together are not well understood. Genes involved in stabilization of the mature 
acinar cell phenotype often have altered expression in pancreatic injury models (Jensen et 
al., 2005; Kowalik et al., 2007). In contrast, mutations of developmental genes are rare in 
PDAC patients, suggesting alternative mechanisms promote acinar cell de-differentiation 
and cancer progression. Our lab has identified Activating Transcription Factor 3 (ATF3), 
a transcription factor upregulated following activation of the unfolded protein response 
(UPR), as a potential factor affecting acinar cell gene expression during pancreatitis 
leading to acinar-to-duct cell metaplasia (ADM), a precursor phenotype of PDAC (Jensen 
et al., 2005; Shi et al., 2013). The goal of my research is to determine whether ATF3 is a 
potential link between chronic pancreatitis (CP) and increased susceptibility to PDAC, 
and to elucidate the signalling pathways by which ATF3 regulates ADM.  
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1.2 Pancreatitis 
The pancreas develops from the endoderm and is divided into endocrine and exocrine 
portions (Jennings et al., 2015). The exocrine pancreas represents 98% of the total 
volume and is composed of two specialized cell types: acinar cells and duct cells 
(Williams, 2010). Acinar cells are responsible for the release of digestive pro-enzyme 
containing zymogen granules, while duct cells release enzymes, ions and water into the 
gastrointestinal tract (Williams, 2010; Reichert & Rustgi, 2011). Dysregulation of 
exocytosis can lead to initiation of the inflammatory response, and loss of epithelial 
tissue. This pathological process is known as pancreatitis. Pancreatitis is a disease of the 
pancreas associated with auto-digestion leading to inflammation and fibrosis (Roberts, 
2015; Storz, 2017). Pancreatic enzymes are pre-maturely activated in acinar cells leading 
to tissue destruction (Papachristou et al., 2007). Acute episodes of pancreatic injury are 
reversible, and complete pancreatic regeneration occurs within 7 days in mouse models 
of pancreatitis (Grady et al., 1998; Yadav et al., 2011). However, chronic injury leads to 
extensive damage and fibrosis through alterations in cell organization, cytokine 
production and stellate cell activation (Grady et al., 1998; Papachristou et al., 2007; 
Aghdassi et al., 2011). Most cases of pancreatitis are caused by excessive alcohol 
consumption, or gall stone obstruction from the bile duct (Roberts, 2015). In addition, 
there are cases of hereditary pancreatitis, in which certain genetic mutations promote 
disease progression (Aghdassi et al., 2011; Roberts, 2015). These mutations are typically 
related to digestive enzyme activation, such as PRSS1 (cationic trypsinogen gene), 
SPINK1 (serine protease inhibitor Kazal type I), and CTRC (chymotrypsinogen C) 
(Whitcomb, 2010; Roberts, 2015). 
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Patients diagnosed with pancreatitis are more likely to develop PDAC (Lowenfels, 2006; 
Yadav et al., 2011), which is associated with extensive fibrosis, inflammatory infiltration, 
and acinar cell atrophy (Logsdon & Ji, 2013). The factors that link these diseases together 
are not well understood and therefore understanding the mechanisms of pancreatic injury 
are crucial in developing preventative or therapeutic strategies to decrease the incidence 
of PDAC.  
1.2.1 Cell Responses to Injury 
Following pancreatitis, the pancreas is challenged to regenerate and replenish damaged 
cells (Murtaugh & Keefe, 2015). Injury stimulates a de-differentiation of acinar cells to a 
progenitor-like phenotype, followed by proliferation, before re-differentiation into mature 
acinar cells (Jensen et al., 2005; Hess et al., 2011). However, if this regenerative process 
is compromised by recurrent injury, the ability of cells to re-differentiate to the acinar 
phenotype is lost and this leads to an increased potential for oncogenic transformations. 
This process is termed acinar-to-ductal metaplasia (ADM), and has been extensively cited 
as a precursor phenotype to PDAC (Logsdon & Ji, 2009; Morris et al., 2010; Shi et al., 
2013; Krah et al., 2015). Histologically, ADM appears in both human and mouse tissue 
as the accumulation of tubular complexes (Figure 1.1; Hess et al., 2011; Prevot et al., 
2012). While there is still debate regarding the true cellular basis of pancreatic 
metaplasia, it is widely accepted that ADMs are derived, at least in part, from an existing 
acinar population that has undergone de-differentiation (Means et al., 2005; Houbracken 
et al., 2016). ADM is an early event in PDAC development and is thought to be the 
source of neoplasias  
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Figure 1.1 Schematic illustration depicting acinar-to-duct cell metaplasia 
Following pancreatitis, acinar cells are stimulated to de-differentiate in an attempt to 
repopulate damaged areas. If this process is compromised, acinar cells can de-
differentiate into a progenitor-like cell, then re-differentiate into a duct-like cell in a 
process term acinar-to-duct cell metaplasia (ADM). This process is driven by decreases 
in the acinar transcriptional program (Mist1, Nr5a2, Rbpjl), and increases in progenitor 
and ductal programs (Sox9, Pdx1, Rbpj, Krt19).  
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(Scotti et al., 2012). These cells transform into pre-malignant cells, and can become 
cancerous when persistent growth factor signalling is present (Ebine et al., 2016). 
Development of the ADM phenotype occurs through a fine-tuned transcriptional program 
in which there is a loss of the mature acinar program, and an upregulation of the 
progenitor and ductal program (Rooman & Real, 2012; Ebine et al., 2016). Identifying 
the molecular factors responsible for this transformation is crucial to understand the 
initiation of the ADM process, and how this increases susceptibility to PDAC 
development (Figure 1.1).  
1.2.2 Cellular and Molecular Events in ADM 
Several transcription factors are responsible for regulating the acinar differentiation 
program. When these factors become differentially expressed, either through 
experimental knockout models, or downregulation in human disease, loss of acinar 
identity occurs thereby allowing ADM (Prevot et al., 2012; von Figura et al., 2014; Storz, 
2017). Normal acinar and duct development occurs through a differentiation process 
whereby endoderm cells differentiate to pancreatic progenitor cells through combined 
expression of pancreatic and duodenal homeobox 1 (PDX1), pancreas transcription factor 
1a (PTF1A), recombining binding protein suppressor of hairless (RBPJ) and Sry-related 
high-mobility group box 9 (SOX9) (von Figura et al., 2014; Jennings et al., 2015; Storz, 
2017). Acinar cells require the expression of PTF1A/RBPJL, nuclear receptor subfamily 
5 group A member 2 (NR5A2), MIST1 and GATA6 for complete differentiation, 
whereby ductal cells differentiate through factors such as hepatocyte nuclear factor 6 
(HNF6), and SOX9 (Pin et al., 2000; von Figura et al., 2014; Jennings et al., 2015). Re-
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establishing a progenitor-like transcriptional profile is part of the process of ADM 
(Figure 1.1, Means et al., 2005).  
A key regulator for the maintenance of acinar cell identity is MIST1, a basic helix-loop-
helix (bHLH) transcription factor responsible for regulating acinar cell maturation and 
function (Pin et al., 2000; Shi, 2009). Germ line deletion of Mist1 leads to incomplete 
acinar cell maturation and pre-mature enzyme activation (Pin et al., 2001; Johnson et al., 
2004). This increases sensitivity to pancreatitis due to changes in intracellular 
communications and exocytosis (Kowalik et al., 2007; Shi, 2009). In addition, Mist1 
deletion in combination with expression of cancer promoting factors (such as activated 
Kirstan Ras (KRAS)) accelerates ADM and PDAC development, while forced Mist1 
expression prevents KRAS-induced neoplasia formation (Shi, 2009; Johnson et al., 
2012).  
RBPJ and RBPJL, contribute to a progenitor or mature acinar cell phenotype, 
respectively, through interaction with the PTF1A complex. In pancreatic progenitor cells, 
RBPJ is part of the PTF1A complex targeting PTF1A to genes involved in cell cycle 
regulation. As cells mature to an acinar cell fate, the PTF1A complex binds to the Rbpjl 
promoter to increase transcription. RBPJL replaces RBPJ in the PTF1A complex and 
binds gene promoters necessary for acinar cell development (Masui et al., 2010; Krah et 
al., 2015). If Ptf1a is lost in murine (6-8 weeks old) acinar cells, they become sensitized 
to KRAS-oncogenic transformation. This prompts rapid and extensive ADM (Krah et al., 
2015).  
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NR5A2 is another factor that co-operates with the PTF1 complex to regulate acinar 
function through maintenance of genes involved in exocytosis. NR5A2 is of particular 
interest in an injury model as it is critical for regeneration following acute pancreatitis 
(von Figura et al., 2014). While not necessary for pancreatic development, loss of Nr5a2 
leads to a downregulation of factors indicative of terminally differentiated acinar cells 
(i.e. Mist1 and Carboxypeptidase A1 (CPA1)), and ultimately increases the capacity of 
acinar cells to undergo ADM (von Figura et al., 2014). This creates a permissive 
environment to drive neoplasia and cancer. In contrast, GATA6 is required for complete 
maturation and maintenance of acinar differentiation by regulating gene expression of 
maturation factors such as Mist1 and Rbpjl (Martinelli et al., 2016). Loss of GATA6 
results in acinar atrophy, incomplete acinar differentiation, and promotes persistent ADM 
(Martinelli et al., 2016; Storz, 2017). Evidence of GATA6 loss in human PDAC suggests 
that it acts as a tumour suppressor, since increased expression locks epithelial cells in a 
differentiated state, and blocks cancer formation (Martinelli et al., 2016).  
Expression of progenitor and ductal markers are essential in driving the metaplastic 
phenotype (Means et al., 2005; Ebine et al., 2016; Storz, 2017). In normal acinar cells, 
Sox9 is expressed in low levels (Jensen et al., 2005; Storz, 2017). Ductal factors are 
expressed in pancreatic acinar cells prior to transformation, thereby priming cells for 
ADM. HNF6 is responsible for inducing Sox9 expression, which remains elevated in 
ADM (Prevot et al., 2012). SOX9 also induces expression of Krt19, a duct-specific 
marker (Kopp et al., 2012). SOX9 is required for neoplastic formation, as loss of Sox9 in 
combination with additional PDAC promoting factors did not affect pancreas 
morphology (Kopp et al., 2012). In addition to Sox9, Pdx1 is upregulated during 
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pancreatitis and PDAC, and is believed to aid in driving the process of ADM (Miyatsuka, 
2006; Storz, 2017). Pdx1 is expressed in pancreatic progenitor cells, which give rise to 
specialized cells of both endocrine and exocrine tissue. Pdx1 is typically downregulated 
after late embryonic development, but is increased in patients and mouse models of 
PDAC (Miyatsuka, 2006). PDX1 regulates ADM through signal transducer and activator 
of transcription 3 (STAT3), a regulator of stem cell self-renewal and inflammation 
(Miyatsuka, 2006).  
These changes in gene expression that occur are a result of acinar cell plasticity (Stanger 
& Hebrok, 2013). When exposed to injury, acinar cells readily de-differentiate to 
repopulate damaged areas (Jensen et al., 2005). In addition to these genetic changes that 
drive the ADM process, additional signalling pathways are upregulated that are known to 
initiate and maintain the de-differentiation and trans-differentiation processes.  
1.3 Signalling Pathways in Acinar-to-Duct Metaplasia 
Pancreatitis leads to activation of signalling pathways that are required to initiate and 
maintain the de-differentiation and trans-differentiation processes. In vitro evidence 
suggests that multiple factors are implicated in driving the ADM process, including 
increased epidermal growth factor receptor (EGFR) signalling (Means et al., 2005; 
Ardito et al., 2012; Eser et al., 2014). ADM was demonstrated in 3D acinar cultures 
following EGFR pathway activation (Means et al., 2005; Scotti et al., 2012). Therefore, 
understanding EGFR signalling, and its effects in cancer development, is necessary to 
determine increased susceptibility to PDAC following chronic pancreatitis.  
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EGFR has been implicated in the pathogenesis of many epithelial cancers through 
inappropriate activation caused by mutations or increased expression of ligands. EGFR is 
a cell surface receptor belonging to the ErbB family of tyrosine kinases (Ardito et al., 
2012; Yewale et al., 2013). EGFR consists of an extracellular signalling domain, a 
hydrophobic transmembrane domain, an intracellular catalytic tyrosine kinase domain, 
and several cytosolic tyrosine residues. When ligands, such as epidermal growth factor 
(EGF) or Transforming Growth Factor Alpha (TGFα) bind to the EGFR extracellular 
domain, receptor dimerization and activation occurs through auto-phosphorylation 
(Yewale et al., 2013). These phosphorylated regions act as docking sites for cytosolic 
proteins responsible for activating downstream events such as proliferation, survival, and 
cell differentiation (Yewale et al., 2013; Logsdon & Lu, 2016). The activation of EGFR 
leads to induction of several downstream signalling pathways including phosphoinositide 
3-kinase (PI3K), phosphate and tensin homolog (PTEN), protein kinase B (AKT), RAS, 
and janus kinase (JAK)/STAT (Fitzgerald et al., 2015; Logsdon & Lu, 2016). Of 
particular interest to ADM development is the RAS pathway, as mutations in the RAS 
protein, specifically KRAS, have been implicated in PDAC development (Logsdon & Ji, 
2009). The RAS pathway consists of the following proteins: Raf (MAPKKK), MEK1/2 
(MAPKK) and ERK1/2 (MAPK) (Fitzgerald et al., 2015). Raf kinase phosphorylates and 
activates MEK1/2, which in turn can phosphorylate and activate ERK1/2. Active ERK 
proteins activate a variety of downstream cytosolic and nuclear proteins, including 
nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) or Transcription 
Factor AP-1 (JUN), that are responsible for regulating gene expression (Figure 1.2; 
Chang et al., 2003; Molina & Adjei, 2006; Roberts & Der, 2007). 
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Figure 1.2 Schematic depiction of the Epidermal Growth Factor Receptor Signalling 
Pathway 
The Epidermal Growth Factor Receptor (EGFR) Signalling Pathway is responsible for 
regulating cellular processes, such as proliferation and cell cycle progression. Ras 
phosphorylates and activates Raf, which sequentially activates Mek1/2, and then 
ERK1/2. ERK proteins activate cytosolic and nuclear proteins, such as nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFκB) or Transcription Factor AP-1 
(JUN), responsible for regulating gene expression.  
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Dysregulation of the EGFR pathway is common; over 90% of pancreatic cancer cases 
present with a constitutively active mutation in the KRAS protein (Molina & Adjei, 2006; 
Aghdassi et al., 2011; Guerra & Barbacid, 2013; Logsdon & Lu, 2016). The most 
common KRAS mutation, a single nucleotide substitution termed KRASG12D, leads to 
constitutive signalling and increased proliferation and cell survival, promoting a 
cancerous phenotype. Evidence of EGFR signalling in ADM and pancreatic cancer 
development has become a widely studied topic (Molina & Adjei, 2006; Storz, 2017).  
Following exposure of pancreatic injury, acinar cells increase EGFR signalling (Ardito et 
al., 2012). Activation of EGFR signalling in murine pancreata induces ADM and 
formation of PDAC (Means et al., 2005; Scotti et al., 2012). This is a cell autonomous 
event as treatment of isolated primary pancreatic acinar cells with TGFα induces 
transformation into metaplastic duct structures (Means et al., 2005; Liou et al., 2015). 
EGFR is necessary for ADM since inhibition with the EGFR inhibitor erlotinib leads to 
normal, non-transformed tissues that present with less duct-like cells. Complete ablation 
of Egfr eliminates TGFα induced metaplasia in vivo. All components of the EGFR 
pathway are necessary to transduce signals, as inhibition of downstream factors, such as 
MEK, also lead to decreased trans-differentiation (Ardito et al., 2012).  
Evidence of increased EGFR signalling is also present in cases of human pancreatic 
cancer (Molina & Adjei, 2006; Guerra & Barbacid, 2013; Shi et al., 2013). In addition to 
an increased accumulation of EGFR and its ligands in patients with chronic pancreatitis 
and PDAC, there is evidence of KRAS mutations (Molina & Adjei, 2006; Roberts & Der, 
2007; Morris et al., 2010). While direct inhibition of EGFR has not proven to be a 
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successful therapeutic, in combination with additional therapies and signalling blockades 
it may be a promising avenue to explore.  
Mutant forms of KRAS on their own do not cause the development of ADM and PDAC 
(Morris et al., 2010; Eser et al., 2014; Logsdon & Lu, 2016). Secondary events are 
necessary to push the phenotype, including loss of terminal acinar differentiation factors 
(such as Mist1 or Nr5a2), or initiation of inflammatory pathways (Shi, 2009; Masui et al., 
2010; Logsdon & Lu, 2016; Storz, 2017). To fully understand the mechanism by which 
ADM develops, it is important to investigate additional pathways that become affected 
during pancreatitis.  
1.4 The Unfolded Protein Response 
1.4.1 General Overview 
The unfolded protein response (UPR) is a cell stress response mechanism that is activated 
by Endoplasmic Reticulum (ER) stress (Harding et al., 2000; Kubisch et al., 2006; 
Thompson et al., 2009). The UPR is a highly conserved pathway between yeast and 
mammals and serves an important function in maintaining protein homeostasis in the cell 
(Lee et al., 2002; Iwawaki et al., 2010). ER stress occurs when protein folding demand 
exceeds folding capacity. Such demands can be placed on the cell through changes to 
gene expression, gene mutations, or environmental factors such as nutrient starvation, 
ischemia, viruses, or changes in temperature (Lee, 1992; Bernales, 2006; Wu & 
Kaufman, 2006; Maas & Diehl, 2015). These changes can be detrimental to normal cell 
function, so the cell must find ways to accommodate these changes to persist survival. To 
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do so, the cell activates the UPR, which involves signaling between the ER and the 
nucleus (Bernales, 2006; Wu & Kaufman, 2006; Thompson et al., 2009).  
Under physiological conditions, plasma membrane proteins travel to the ER where proper 
folding is facilitated by ER-resident chaperones. If the ER senses an increased demand 
for folding capacity, the UPR is activated leading to enlargement of the ER, and 
increased expression of chaperone proteins (Harding et al., 2000; Kubisch et al., 2006; 
Sah et al., 2014). However, if the cell is stressed beyond the point of capacity, the UPR 
activates pathways to decrease protein translation, decrease overall loading of proteins 
onto the ER, or target unfolded/misfolded proteins for degradation, via ER associated 
degradation (ERAD) (Wu & Kaufman, 2006; Wu et al., 2007; Maas & Diehl, 2015). If 
the UPR is activated for a prolonged period, and none of these mechanisms compensate 
for the changes in protein levels to restore homeostasis, the cell will be targeted for 
apoptosis to prevent accumulation of damaged proteins (Lee et al., 2002; Bernales, 
2006). The coping mechanisms outlined above are activated through three specific arms 
of the UPR pathway: PKR-like Endoplasmic Reticulum Kinase (PERK), Inositol-
requiring enzyme 1 (IRE1), and Activating Transcription Factor 6 (ATF6) (Lee, 1992; 
Haze et al., 1999; Harding et al., 2000; Bernales, 2006; Liang et al., 2006).  
PERK, IRE1, and later ATF6, are activated in response to ER stress through dissociation 
from BiP/GRP78, an ER resident chaperone protein part of the Hsp70 family (Wei et al., 
1995; Bernales, 2006). The first immediate response is PERK and IRE1. Each pathway is 
activated by dimerization, and autophosphorylation (Harding et al., 2000; Ron et al., 
2000). PERK pathway activation leads to eukaryotic initiation factor 2 alpha (eIF2α) 
phosphorylation, decreased protein translation in the cell, and increased translation of 
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downstream proteins (ATF4) that function as transcription factors (Haze et al., 1999; 
Bernales, 2006; Zhang et al., 2008). IRE1 activates endoribonuclease activity, leading to 
altered splicing of X-box-binding protein (Xbp) 1 mRNA, allowing it to generate a 
transcription factor (spliced [s] XBP1), which increases expression of ER-chaperone 
proteins and activates ERAD (Calfon et al., 2002; Lee et al., 2002; Wu & Kaufman, 
2006; Sah et al., 2014). ATF6 becomes activated through translocation to the cis-golgi 
compartment, where it is cleaved by site-1 and -2 proteases. Cleaved ATF6 is then 
translocated to the nucleus to increase transcription of ER-chaperone proteins, and elicit 
transcriptional activity alongside ATF4 and sXBP1 (Haze et al., 1999; Bernales, 2006; 
Wu & Kaufman, 2006). These pathways function to maintain physiological levels of 
protein in the cell (Figure 1.3). This is especially important in pancreatic acinar cells, as 
they are subjected to high levels of stress, due to the higher than average protein demand 
(Kubisch et al., 2006; Iwawaki et al., 2010). While the primary function of the UPR is to 
maintain homeostatic levels of protein, it can contribute to development of pathological 
processes as well, including pancreatitis (Kubisch et al., 2006; Lugea, 2011; Sah et al., 
2014; Karki et al., 2015).  
1.4.2 Involvement of UPR in Pancreatitis and PDAC 
Due to the acinar cells’ large demand for protein synthesis and activity, they are 
subjected to higher than normal stress levels (Kubisch et al., 2006). Acute or chronic 
exposures to elevated stress signals leads to disruption in protein homeostasis in the cell, 
and initiation of pancreatitis. The ER stress response becomes activated in stressed  
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Figure 1.3 The Unfolded Protein Response 
The unfolded protein response (UPR) is a cell stress mechanism responsible for 
maintaining protein homeostasis. The Endoplasmic Reticulum (ER) senses when the 
protein folding demand of the cell exceeds its capacity. The ER will activate 3 specific 
signalling pathways, PKR-like Endoplasmic Reticulum Kinase (PERK), Inositol-
requiring enzyme 1 (IRE1), and Activating Transcription Factor 6 (ATF6), in an attempt 
to decrease protein translation, decrease protein load, target proteins for degradation, and 
finally if stress is unresolved, activate cellular apoptosis. All 3 pathways are responsible 
for activating proteins that will act as transcription factors to aid in activation and 
regulation of these processes (Cláudio et al., 2013). 
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pancreatic acinar cells, as evidenced by increased expression of genes that are targets of 
ER stress mechanisms (Sah et al., 2014). Pancreatic acinar cells increase the ER stress 
response in response to multiple environmental stimuli used in mouse models of 
pancreatitis, including forced cholecystokinin (CCK) receptor activation through cerulein 
injections, injections of L-arginine, and through ethanol feeding (Liang et al., 1996; 
Kubisch et al., 2006; Kowalik et al., 2007; Lugea, 2011).  
Regardless of the method by which pancreatitis is initiated, the UPR is rapidly activated. 
Following induction of pancreatitis by cerulein injections, PERK and IRE1 are activated 
by autophosphorylation (Liang et al., 2006). A similar effect is observed when mice are 
administered L-arginine, as activation of all major UPR pathways were detected within 4 
hours of pancreatitis initiation (Lugea, 2011). While chronic alcohol consumption may be 
a predisposing factor to pancreatitis development in murine models and humans, 
exposure to this insult alone does not cause the disease to progress. However, ethanol 
exposure leads to increased UPR activity, as evidenced by increased spliced XBP1 levels 
(Lugea, 2011; Alahari et al., 2011). This may underlie the susceptibility to pancreatitis if 
the acinar cells are exposed to additional injury. In addition to UPR activation in the L-
arginine and cerulein treated models, there is evidence of upregulation of downstream 
transcription factors that regulate the UPR response, such as ATF4, ATF3, and 
CCAAT/enhancer-binding protein alpha (C/EBPα) (Ji et al., 2003; Kubisch et al., 2006). 
The primary function of the UPR is to maintain protein homeostasis (Bernales, 2006). 
However, in instances where the cell has an overwhelming amount of damaged protein, 
prolonging survival of the cell may be detrimental. In this case, the UPR now becomes 
pathological. This is especially true of cancerous cells (Gifford et al., 2016). Cancer cells 
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are constantly under ER stress due to hypoxic conditions, low nutrients, and high loads of 
mutant protein (Namba & Kodama, 2015). There is evidence in pancreatic cancer that the 
UPR promotes chemo-resistance through BiP/GRP78 expression. GRP78, an ER-
chaperone protein, activates anti-apoptotic pathways leading to chemo-resistant tumours. 
This demonstrates how UPR activation, and in turn BiP/GRP78 expression, can no longer 
function to maintain physiological protein levels, but actually promote a cancerous 
phenotype (Gifford et al., 2016).  
Defining the function of downstream transcription factors of the UPR will help in 
understanding the role of the UPR in pancreatitis and PDAC development. Since these 
factors do not have roles exclusive to protein homeostasis but may also contribute to the 
promotion of pancreatic disease, studying them may identify mechanisms of pancreatic 
disease development.  
1.5 Activating Transcription Factor 3 
1.5.1 General Overview 
The activating transcription factor/cAMP responsive element binding (ATF/CREB) 
proteins belong to the basic leucine zipper (bZIP) family of transcription factors. All 
ATF/CREB proteins bind to similar consensus sites and can be grouped based on their 
amino acid similarities (Hai & Hartman, 2001). These subgroups include ATF1, 2, 3, 4, 
6, and 7, which share the bZIP binding element (Hai & Hartman, 2001; Thompson et al., 
2009). BZIP proteins can bind to DNA as homodimers with each other, or heterodimers 
with other transcription factors including C/EBP, AP1, p53, and SMAD (Thompson et 
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al., 2009; Wang et al., 2015). Depending on the binding partner, this can affect the DNA 
binding specificity and transcriptional activities (Hai & Hartman, 2001).  
ATF3 is 181 amino acids, has a molecular mass of 22 kDa, and has only one defined 
functional domain - the bZIP domain (Thompson et al., 2009). ATF3 interacts with other 
ATF/CREB proteins, and depending on the promoter it is bound to, can act as an 
activator or repressor of transcription (Hai & Hartman, 2001; Thompson et al., 2009). 
The Atf3 promoter contains ATF/CRE and AP1 sites indicating it is regulated by other 
ATF proteins. Atf3 is a stress-inducible gene. Atf3 mRNA expression is low in quiescent 
cells, but is induced by a variety of stress signals (Hai & Hartman, 2001; Lu et al., 2006; 
Thompson et al., 2009). ATF3 expression is increased in a variety of tissues, including 
heart, liver, kidney, and skin, in response to ischemia, hypoxia, direct mechanical or 
chemical injury, or wounding (Hai & Hartman, 2001; Pelzer et al., 2006; Lu et al., 2006; 
Li et al., 2010). Cellular stress signals, such as elevated temperature, cytokine, genotoxic 
agents, cytotoxic agents, ER stress and DNA damage, also increase ATF3 expression in 
vitro (Li et al., 2010; Wang et al., 2015; Zhao et al., 2016).  
Atf3 mRNA expression is increased within 2 hours of stress stimulation in mouse 
embryonic fibroblast cells, in this case by thapsigargin treatment and amino acid 
starvation (Liang et al., 1996; Jiang et al., 2004). This quick response indicates its direct 
activation by cellular stress response mechanisms, such as the UPR (Liang et al., 1996; 
Bernales, 2006). Studies have shown that activation of the UPR leads to phosphorylation 
and increased expression of ATF2 and cJUN, through activation of the IRE1 pathway 
(Jiang et al., 2004), which can target and regulate promoters containing ATF/CRE or 
AP1 sites (Liang et al., 1996). cJUN and ATF2 have been shown to work in co-operation 
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to bind to the Atf3 promoter and activate its transcription (Liang et al., 1996; Jiang et al., 
2004). In addition, other arms of the UPR pathway, such as PERK or ATF6, have also 
been shown to increase Atf3 expression (Jiang et al., 2004; Kowalik et al., 2007). The 
PERK pathway, upon stress induction, leads to phosphorylation of eIF2α, which blocks 
its ability to associate in a transcriptional complex, and decreases protein translation and 
increases ATF4 expression. ATF4 goes on to then increase Atf3 expression through 
binding to a C/EBP-ATF response element (CARE) located on the Atf3 promoter (Figure 
1.4) (Bernales, 2006; Kowalik et al., 2007; Fu & Kilberg, 2013). Atf3 expression is then 
maintained through blocking of the negative feedback mechanism on eIF2α (Kowalik et 
al., 2007). The activation of ATF3 is dependent on this pathway as deletion of eIF2 
kinase blocks synthesis of Atf3 mRNA and protein (Jiang et al., 2004). As well, in 
conjunction with eIF2α, ATF6 increases expression of Atf3 (Kubisch et al., 2006). 
Atf3 expression is increased through cellular stress mechanisms both directly and 
indirectly (Hartman et al., 2004; Li et al., 2010; Kwon et al., 2015). The increase in 
expression following stress exposure suggests the roles ATF3 may play following UPR 
activation. Understanding how ATF3 may be eliciting its effects as a transcription factor 
will provide insight into how it may regulate outcomes in damaged acinar cells.   
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Figure 1.4 Schematic illustration of the pathways responsible for UPR-mediated 
induction of ATF3 expression 
Activating Transcription Factor 3 (ATF3) is activated by the UPR through a variety of 
cellular stresses. Specifically, PERK proteins sense unfolded proteins in the extracellular 
space and phosphorylates and de-activates eiF2α, leading to decreased protein translation 
and increased ATF4 expression. ATF4 then translocates to the nucleus where it binds to 
C/EBP-ATF response element (CARE) sequences in the ATF3 promoter, activating its 
expression.  
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1.5.2 ATF3 Transcriptional Activity 
There is some evidence that when ATF3 binds as a homodimer, it acts a transcriptional 
repressor, and when bound as a heterodimer, it activates transcription (Zhao et al., 2016). 
ATF3 also exists in an alternatively spliced form that lacks the leucine zipper. The two 
splice forms of the protein have different transcriptional functions. It has been suggested 
that the full length isoform (181 amino acids) may repress rather than activate 
transcription (Hashimoto et al., 2002; Thompson et al., 2009; Wang & Yan, 2015; Kwon 
et al., 2015). The truncated ATF3 protein, termed ATFΔZip (135 amino acids), lacks the 
leucine zipper domain, and can therefore not bind to DNA. This shorter isoform can 
however bind to other transcription factors, and thereby inhibit binding to promoter 
regions leading to inhibition of transcription (Hashimoto et al., 2002; James et al., 2006; 
Wang & Yan, 2015; Kwon et al., 2015).  
More recently it has been recognized that the function of ATF3 depends on the 
transcriptional complex it is a part of and the promoter region it is bound to, therefore the 
role of ATF3 as a repressor or activator cannot be generalized (Thompson et al., 2009, 
Zhao et al., 2016). ATF3 activates transcription through direct protein-protein 
interactions with DNA damage inducible transcript 3 (CHOP), which leads to apoptosis 
(Liang et al., 1996). ATF3 may also regulate gene expression through direct promoter 
interactions, as evidenced by reduced inflammatory activation in injured kidney cells 
when ATF3 recruits inhibitory histone deacetylase (HDAC) 1 to the NFκB promoter (Li 
et al., 2010). ATF3 not only binds to promoter regions to elicit its effects, but also 
interacts with enhancer regions, as defined by binding to p300 and K27 acetylated histone 
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H3 (H3k27ac) sites (Zhao et al., 2016). In fact, ATF3 may act as a “primer” for other 
activating or repressing transcription factors, serving to recruit these proteins to enhancer 
regions to affect the transcriptional program (Zhao et al., 2016). Overall, ATF3 plays a 
complex role in regulating transcriptional programs, and the protein interactions and 
genomic sites where ATF3 binds will define how and which transcriptional programs are 
being regulated (Li et al., 2010; Zhao et al., 2016) 
1.5.3 Physiological protective roles of ATF3  
ATF3 has been shown to have protective roles in certain physiological processes 
including inflammation and apoptosis. Specifically, ATF3 has been shown to negatively 
regulate transcription of pro-inflammatory cytokines and function as a tumour suppressor 
(Huang et al., 2008; Li et al., 2010; Kwon et al., 2015).  
Deletion of Atf3 in primary macrophages leads to elevated expression of interleukin (IL)-
6 and IL-12p40 pro-cytokines. This is specific to asthma, an inflammatory disease of the 
lungs, where Atf3 null mice exhibit increased airway resistance corresponding to 
increased inflammatory cell infiltration (Gilchrist et al., 2008; Thompson et al., 2009). In 
addition to the roles in lung tissue, ATF3 has been shown to protect against acute kidney 
injury through regulation of NFκB in both a direct and indirect manner. Directly, ATF3 
inhibits the inflammatory response following acute kidney damage by binding to the p65 
subunit of NFkB, preventing nuclear translocation and downstream activation of 
inflammation (Kwon et al., 2015). Indirectly, ATF3 recruits inhibitory HDAC1 to the 
NFkB promoter, therefore inhibiting expression of pro-inflammatory factors (Li et al., 
2010). 
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In addition to these anti-inflammatory effects, ATF3 can act in prostate cancer cells to 
induce apoptosis. KLF6, a tumour suppressor gene, acts directly on the Atf3 promoter to 
increase expression, leading to apoptosis. The role of ATF3 as a tumour suppressor is 
supported by gene knockdown experiments, where loss of Atf3 blocks apoptosis in 
prostate cancer cell lines (Thompson et al., 2009; Wang et al., 2015; Ebine et al., 2016). 
Similarly, ATF3 functions in breast cancer cells to induce apoptosis and decrease 
metastatic potential. There is evidence that high progesterone levels, present in ovarian 
cancer (OVCA) cell lines, upregulates expression of Atf3 and apoptosis. As well, ATF3 
has been implicated in regulating the metastatic potential of OVCA cells as ectopic 
overexpression of ATF3 decreases invasiveness compared to controls (Syed et al., 2005; 
Thompson et al., 2009). Overall, these studies suggest the role of Atf3 in decreasing the 
oncogenic potential in prostate and breast cancer cells through its ability to increase 
apoptosis and decrease invasiveness. 
While ATF3 has been shown to have a protective role in certain physiological processes, 
such as inflammation or tumour suppression, there is evidence to suggest that it may have 
detrimental roles as well, and function to promote and maintain a pathological outcome 
(Bandyopadhyay et al., 2006; Pelzer et al., 2006; Thompson et al., 2009).  
1.5.4 ATF3 in pathology 
Expression of ATF3 is induced by elevated stress through direct disruption of normal cell 
function, such as DNA damage, or through cancer promoting environmental signals, such 
as ultraviolet radiation (Pelzer et al., 2006; Zhao et al., 2016). Since ATF3’s expression 
is associated with pathological factors, it is predictive that ATF3 would then be 
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associated with promoting oncogenic transformation of cells. This occurs in many tissues 
such as breast cancer, prostate cancers and lymphomas (Thompson et al., 2009). 
Although ATF3 can inhibit cell cycle progression in cancer cells, thereby decreasing 
cancer growth, there is evidence that overexpression of ATF3 in human prostate cancer 
cell lines led to increased proliferation and G1 to S growth phase transition (Pelzer et al., 
2006), while also promoting metastasis and increased invasiveness (Bandyopadhyay et 
al., 2006). A similar effect is evident in Hodgkin lymphoma cells, where Atf3 expression 
is increased through activation of c-JUN, and leads to increased proliferation and 
viability of these cells (Janz et al., 2006). ATF3’s regulation of these pro-cancer 
processes may be through inhibition of GADD153. Binding of ATF3 to the GADD153 
promoter of HeLA cells induces cell cycle arrest and apoptosis provides mechanism to its 
oncogenic properties (Hartman et al., 2004; Jiang et al., 2016).  
In addition to the role of ATF3 in cancer development, ATF3 can affects cell 
differentiation. While there is evidence for the role of ATF3 in promoting terminal 
differentiation (James et al., 2006), it has also been implicated in cell de-differentiation. 
ATF3 represses adipocyte differentiation through direct transcriptional regulation. 
C/EBPα and PPARγ are transcription factors that play a critical role in the expression of 
adipose differentiation genes. Overexpression of ATF3 in 3T3-L1 cells, a cell line 
derived from fibroblasts, represses adipocyte differentiation through binding to ATF/CRE 
sites on the C/EBPα promoter (Jang et al., 2012).  
The presence of ATF3 in a variety of pathological tissues indicates the detrimental role it 
may play. Based on the literature, it is clear that the function of ATF3 can vary greatly 
depending on the tissue type and cell conditions. To understand the role that Atf3 plays in 
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pancreatitis and ADM development, it is first necessary to explore its mechanism of 
action in other pancreatic processes.  
1.5.5 ATF3 in the pancreas 
In addition to the prominent roles ATF3 plays in apoptosis, cellular function and 
differentiation in other tissue types, there is evidence that ATF3 affects several processes 
in the pancreas. In pancreatic β-cells, ATF3 has been implicated in apoptosis, 
differentiation and increasing cell dysfunction (Piper et al., 2004; Hartman et al., 2004; 
Jang, 2011).  
β-cell death is a significant factor in the etiology of type 1 and type 2 diabetes. Patients 
with these diseases show increased levels of Atf3 in their islets. Cell death is promoted in 
this tissue through increased activation of NFκB and JNK signalling, both of which are 
responsible for activating Atf3 expression. Atf3 has been implicated in β-cell apoptosis, as 
islets deficient in ATF3 are protected from cytokine- and nitric oxide-induced apoptosis. 
The mechanism by which this occurs is speculated to be through direct interactions with 
Gadd34/CHOP. The formation of this complex leads to increased expression of specific 
pro-apoptotic genes. In this instance, the role of Atf3 in the pancreas is detrimental to its 
function (Hartman et al., 2004).  
Atf3 has also been shown to play a pathological role in β-cell function. A study by Jang et 
al. in 2011 explores the role of ATF3 in regulating PDX1, a key factor of pancreatic 
development, β-cell differentiation, regeneration and maintenance of function. Activation 
of the ER stress pathway in β-cells affects PDX1 transcriptional activity. Since Atf3 
expression is upregulated during cell stress, its role in regulating Pdx1 expression are 
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clear. Over-expression of ATF3 decreases Pdx1 expression in β-cells through direct 
interactions with the Pdx1 promoter, as mutations of the ATF3 binding site in the Pdx1 
promoter disrupted this repressive activity. Repression of Pdx1 by ATF3 leads to 
suppression of insulin expression and secretion, decreasing β-cell functionality (Jang, 
2011). 
In addition to the role ATF3 plays in repressing β-cell functionality, it may also affect β-
cell differentiation and development. When Atf3 is expressed using a transthyretin (TTR) 
promoter, which is specific to endocrine tissue, pancreatic development is disrupted 
resulting in reduced islet number, or in some cases, a complete lack of islets (Allen-
Jennings et al., 2001). There is evidence that mechanistically, ATF3 causes this to occur 
through regulation of Pdx1. Pdx1 expression is increased in islets during embryonic 
development, and its expression is maintained in mature islets. Since ATF3 affects Pdx1 
expression, it may also play a role in regulating the cell differentiation process (Piper et 
al., 2004; Jang, 2011). The role of ATF3 in repressing Pdx1 transcriptional activity in 
endocrine tissue alludes to its potential effects in exocrine tissues. 
While Atf3 has been explored in the endocrine pancreas, there is little evidence of its role 
in exocrine tissue. Studies have identified the effects of ER stress response on acinar cell 
function, but none have examined the direct effects of ATF3 and its ability to modulate 
transcriptional activity in this tissue type.  
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1.6 Rationale, Objectives, Hypothesis 
1.6.1 Rationale and Previous Work 
PDAC is the most common disease of the pancreas and is difficult to treat and diagnose 
(Yadav & Lowenfels, 2013; Eser et al., 2014). Patients present with a lack of symptoms 
until tumour progression has become advanced, leading to a poor prognosis. Pancreatic 
cancer is the 3rd most common cause of cancer-related death, and incidence continues to 
rise (Yadav & Lowenfels, 2013; Cid-Arregui & Juarez, 2015; Siegel et al., 2017). 
Diagnosis of this cancer remains difficult, as there are no specific tests to detect 
malignancy, and signs and symptoms of this disease can be easily mistaken for other 
ailments (Cid-Arregui & Juarez, 2015). Current treatment strategies include pancreatic 
resection followed by systemic chemotherapy, including administration of gemcitabine 
(Cid-Arregui & Juarez, 2015). However, these protocols show limited efficacy, and over 
95% of patients die within 5 years of diagnosis (Yadav & Lowenfels, 2013). 
Understanding the mechanisms by which patients develop increased susceptibility to 
cancer following pancreatitis is crucial to develop preventative, diagnostic and treatment 
strategies.  
Uncovering how ATF3 affects ADM development may aid in understanding PDAC 
initiation and progression. Previous results from our laboratory show that intraperitoneal 
(I.P.) injection of Atf3-/- mice with cerulein leads to increased pancreatic damage and 
fibrosis 4 hours following injury. However, Atf3-/- mice present with healthy acinar tissue 
following a period of pancreatic regeneration (72 hours following injury) compared to 
wild type mice, which show increased ADM, fibrosis, and damage. RNA-sequencing 
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analysis demonstrates that ATF3 affects genetic expression of transcription factors 
required for pancreatic terminal differentiation, indicating it may be priming injured 
acinar cells for pathogenic de-differentiation and trans-differentiation. Additionally, the 
loss of ATF3 is implicated in decreased EGFR signalling following cerulein 
administration suggesting it may be affecting ADM through this pathway (Fazio et al., 
2017). The main goal of my thesis is to understand how ATF3 promotes ADM through 
either affecting the mature acinar genetic program, or through EGFR signalling.  
1.6.2 Hypothesis 
I hypothesize that ATF3 regulates acinar gene expression promoting acinar-to-duct cell 
metaplasia. 
1.6.3 Objectives and Significance 
1) Determine if factors that regulate acinar cell differentiation are altered in Atf3-/- 
mice  
2) Examine the ability for Atf3-/- acinar cells to undergo ADM in culture  
3) Determine if the absence of ATF3 affects recurrent pancreatic injury 
This work aims to determine whether ATF3 is a key regulator of the ADM process. If the 
mechanism by which ADM develops can be determined, better diagnostic and 
therapeutics can be established which could aid in blocking the progression to PDAC.  
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Chapter 2  
2 Methods 
2.1 Mice 
Mice with a germ line deletion of exon 2 within the Atf3 gene in a C57Bl6 background 
have been described previously (Atf3-/-; Hartman et al., 2004). Two-to-four month old 
mice were used for all experiments and both male and female mice were included.  All 
experiments were conducted with the approval of the Animal Care Committee at the 
University of Western Ontario following protocol guidelines (#2008-117/2017-001). The 
genotypes of the mice were confirmed by polymerase chain reaction (PCR) with the 
following primers: wild-type Atf3 - 5' TGAAGAAGGTAAACACACCGTG 3'; common 
Atf3 - 5' AGAGCTTCAGCAATGGTTTGC 3'; deleted Atf3 - 5' 
ATCAGCAGCCTCTGTTCCAC 3'. The PCR program used was 40 cycles of denaturing 
(95°C for 30 seconds), annealing (63.2°C for 30 seconds), and elongation (72°C for 60 
seconds).  
To initiate acute pancreatic injury, congenic (inbred) wild-type (Atf3+/+) or Atf3-/- mice 
were given intraperitoneal (I.P.) injections of saline (vehicle control) or cerulein (Sigma, 
St. Louis, MO; CIP; 50 µg/kg) once per hour for 4 hours or 8 hours according to a 
previously established protocol (Kowalik et al., 2007). Ceruelin, a CCK analog, activates 
CCK receptors and induces pancreatic enzyme release (Aghdassi et al., 2011). Mice were 
sacrificed at 4 hours or 72 hours following the first injection.  
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Chronic injury was initiated in the mice by injecting saline (vehicle control) or cerulein 
I.P. (250 µg/kg) twice daily for 14 days. This protocol was adapted from a previously 
established protocol (Ardito et al., 2012). Mice were allowed to recover for 7 days before 
sacrifice. During this time period, mice were weighed once daily (a.m.) to assess changes 
in body weight.  
2.2 RNA Isolation, Polymerase Chain Reaction, and 
Quantitative Real-Time PCR 
Upon dissection, a 2-3 mm2 splenic portion of the pancreas was removed and placed in 
TRIzol Reagent (Invitrogen; Carlsbad, CA). A tissue homogenizer was used to break up 
the tissue for 30 seconds. RNA was isolated using the PureLinkTM RNA Minutes Kit 
(ThermoFisher Scientific, Waltham, MA) as per manufacturer’s directions and stored at -
80°C. RNA quality was assessed by RNA Integrity analysis using the Bioanalyzer at 
Roberts Institute at the University of Western Ontario. RNA was quantified using the 
NanoDrop® ND-1000 UV-Vis Spectrophotometer (ThermoFisher Scientific) and 
Nanodrop-1000 software.  
To perform RT-PCR, RNA was used to generate cDNA through a Reverse Transcriptase 
reaction using ImProm-II™ Reverse Transcription System (Promega; Madison, WI). 
Samples were prepared from 1 µg of RNA as per manufacturer’s directions. To determine 
quality of cDNA, PCR was performed using a PCR master mix (10x DreamTaq Green 
Buffer, DreamTaq DNA polymerase (Thermofisher Scientific) and the appropriate 
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diluted primers (20 nM), dH2O) for Mitochondrial Ribosomal Protein (Mrpl) (Table 2.1). 
Samples were stored at -20°C. 
Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was performed using 
GoTaq® qPCR Master Mix (Promega, Madison, WI). Primers for genes of interest were 
diluted to a final concentration of 20 nM and combined with GoTaq® qPCR Master Mix 
and aliquoted (9 µl) to a 365 well plate (see Table 2.1 for primer sequences). qRT-PCR 
was performed on 1 µg/µl of cDNA in 9uL of GoTaq® qPCR Master Mix for each 
sample in triplicate using the ViiA™ 7 qRT-PCR machine (Applied Biosystems; Foster 
City, CA). The program consisted of 40 cycles of denaturing (95°C for 10 seconds), 
annealing (see Table 2.1 for temperatures – for 40 seconds), and elongation (72°C for 10 
seconds). Results were analyzed using the calibrator normalized method with standard 
curves for efficiency correction according to the equation:  
Relative amount = ET CpT(C)-CpT(tS) x ER CpR(tS)-CpR(C)  
Where : 
E = Efficiency (E = 10-1/m; m = slope of standard curve)  
Cp = Crossing point (derived by Lightcycler software version 3.5)  
T = Target gene (i.e. gene of interest)  
R = Reference gene (i.e. housekeeping gene)  
C = Calibrator (e.g. saline control)  
tS = Sample (e.g. treated sample) 
 
 
 
32 
 
 
Table 2.1 Primers used for RT-PCR and qRT-PCR 
Gene Annealing Temp (°C) Fwd Rev 
Mrpl 60 5' TTGGATATGCCAAGTGACCA 3' 5' GCTTCTGCCGTTTGAGTTTC 3' 
Nr5a2 60 5' TGGCGATAAAGTGTCTGGGT 3' 5' CCAGCTTCATCCCAACACG 3' 
Sox9 60 5' CGTGCAGCACAAGAAAGACCA 3' 5' GCAGCGCCTTGAAGATAGCAT 3' 
Krt19 60 5' CCTCCCGCGATTACAACCACT 3' 5' GGCGAGCATTGTCAATCTGT 3' 
Pdx1 63 5' CCACCCCAGTTTACAAGCTC 3' 5' TTCAACATCACTGCCAGCTC 3' 
Rbpj 63 5' GTGTTCCTCAGCAAGCGGATA 3' 5' TGCCACCTTCGTTCCTGA 3' 
Rbpjl 63 5' ATGCCAAGGTGGCTGAGAAAT 3'  5' CTTGGTCTTGCATTGGCTTCA 3' 
Egf 63.8 5’ ATGTGCCACTCAGAATCACG 3’ 5’ AAAGTGCAGTCATGGCTGTG 3’  
Tgfα 63.8 5’ AAGAAGCAAGCCATCACTGC 3’ 5’ CAAGCAGTCCTTCCCTTCAG 3’ 
Egfr 60.8 5’ CTGCCAAGGCACAAGTAACA 3’ 5’ GTTGAGGGCAATGAGGACAT 3’ 
Mek 60.8 5’ GGGGAACTGAAGGATGA 3’  5’ GGAGTTGCACTCGTGCAGTA 3’ 
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2.3 Protein Isolation and Western Blotting 
Protein was isolated from the splenic portion of the pancreas. Tissue was homogenized in 
100-500 µl of protein isolation buffer (50 mM Tris [pH 7.2], 5 mM MgCl2, 1 mM CaCl2, 
10 mM DTT, 1% NP40, 100 units/ml DNAse I, 50 µg/ml RNAse A, 10 mM PMSF, 5 
µg/ml leupeptin, 5 µg/ml aproptinin, 5 µg/ml pepstatin, 50 mM NaF, 2 mM NaVO4 in 
dH2O). Following homogenization, tissue was sonicated continuously for 10-20 seconds. 
Samples were then centrifuged at 4°C for 5 minutes at 5,000g, supernatant was removed 
and samples were stored at -80°C (Pin et al., 2000).  
To isolate protein from primary acinar cells in suspension, media was removed and cells 
rinsed with cold Phosphate Buffer Solution (PBS). Cells were then centrifuged at 16g for 
1 minute to pellet. Cell pellets were mixed with the 100-200 µl of protein isolation buffer 
(described above), and lysed by pipetting up and down several times. Protein was then 
processed using the same methods as above.  
Protein was quantified using the BioRad protein assay, and absorbance was determined 
either in duplicate using the Ultrospec 2100 pro UV-visible spectrophotometer 
(Biochrom, Holliston, MA) at 600 nm or triplicate using the Multiskan Ascent 96/384 
Plate Reader (ThermoFischer Scientific) at 595 nm.  
To perform Western blot analysis, 2 µg, for amylase analysis, or 40 µg for either pERK 
or tERK analysis, of protein was mixed with 5 µl of 5x sodium dodecyl sulfate (SDS) 
loading dye and 1 µl of β-mercaptoethanol, then heated to 100°C for 5 minutes. Samples 
were resolved on a 10% SDS-polyacrylamide gel at 200V. Protein was transferred to 
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PVDF membranes (BioRad; Herculus, CA) at 200 mA for 90 minutes. Following 
transfer, the membrane was rinsed with PBS and incubated at room temperature for 1 
hour in dissolved 5% non-fat dried milk (NFDM) in PBS for 60 minutes. The membrane 
was rinsed with either PBS or 0.1% Tween-20 (Dako; Glostrup Municipality, Denmark) 
in Tris Buffered Solution (TBS; TBST), depending on the antibody used, 3x for 5 
minutes each before incubating with primary antibody. Antibodies against Amylase 
(1:1000; Abcam Inc., Cambridge, UK) were diluted in 5% NFDM in PBS, where as 
phosphorylated-ERK1/2 (1:500; Cell Signaling Technology, Danvers, MA) and total 
ERK (1:250; Cell Signaling Technology, Danvers, MA) were diluted in 5% BSA in 
TBST. Membranes were incubated overnight at 4°C with the primary antibody. Prior to 
adding the secondary antibody, membranes were rinsed 3x 5 minutes with either PBS 
(amylase) or TBST (pERK, tERK). Membranes were incubated in secondary antibody 
(anti-rabbit horseradish peroxidase; Sigma 1:10,000) diluted in 5% NFDM in PBS, for 60 
minutes at room temperature. Following another set of washes as above, the membranes 
were incubated for 2-3 minutes in Clairty MaxTM Western ECL Blotting Substrates 
(BioRad) at a 1:1 dilution. Blots were visualized using the VersaDoc Imaging System 
with Quantity One 1-D Analysis software (BioRad). 
In some instances, the membrane was stripped of primary antibody prior to reprobing. 
The membrane was incubated with stripping buffer solution (100 mM 2-mercaptoethanol, 
62.5 mM Tris HCl [pH 6.7], 2% sodium dodecyl sulfate in dH2O) for 30 minutes at 55°C, 
and was then rinsed with TBS, before washing with TBST for 7 minutes. The membrane 
was washed 2 x 5 minutes each with TBS before adding 5% NFDM in PBS blocking 
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solution for 60 minutes. The membrane was processed following the same protocol as 
described above.  
2.4 Acinar Cell Isolation and Culture 
To establish acinar cell cultures, fresh pancreata from 2-4 month old male and female 
wild type and Atf3-/- mouse were dissected and immediately incubated in DMEM media 
(Gibco, ThermoFisher Scientific) supplemented with 1% Penstrep and 0.1% soybean 
trypsin inhibitor, previously diffused with oxygen (oxygenation) for 20 minutes. 
Oxygenation occurs by bubbling oxygen from an oxygen tank through media using a 
glass pipette. Pancreatic tissue was repeatedly injected with DMEM containing 
collagenase (200 µL of 1000U/10 ml) using a 1 mL syringe and 26.5 gauge needle. Once 
the pancreas was distended, it was cut into smaller pieces oxygenated for 1 minute, then 
rocked at 120 oscillations per minute in a 37°C incubator for 10 minutes. The DMEM-
collagenase solution was replaced with fresh solution, and oxygenation repeated for an 
additional 40 minutes. The tissue homogenate was disrupted further by pipetting though a 
10 mL, then 5 mL serological pipette. Homogenates were strained though a 105 µm 
nylon mesh filter. The nylon filter was washed with DMEM containing 4% Bovine 
Serum Albumin Fraction V (BSA; Roche, Basel, Switzerland). At this point, the tissue 
homogenate consisted of individual, or small clumps of acini. The tissue homogenate was 
divided into 4 samples, and each centrifuged at 45g for 3 minutes to pellet the acini. The 
supernatant was removed, and acini washed with 40 mL of DMEM+4% BSA. Acini were 
pelleted as described above, and 2 subsequent washes were repeated with DMEM 
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containing 1% BSA. Acini were combined to one tube, and incubated at 37°C for 15 
minutes.  
Acini were cultured in RPMI media (Gibco, ThermoFisher Scientific, supplemented with 
1% Penstrep, 1% Newborn Calf Serum (NCBS), 0.1% soybean trypsin inhibitor and 1% 
dexamethasone) overnight for protein isolation, or embedded in collagen. To embed acini 
in collagen, supernatant was removed and acini were resuspended in a 1:1 ratio of RPMI 
media and Rat Tail Type 1 Collagen (3.68 mg/ml; Corning, Corning, NY). Neutralization 
buffer (2:3 ratio of 0.34 M NaOH and 10x Waymouth Media) was added drop wise to the 
acini and collagen solution under mild vortexing. Acini were plated in 3 cm dishes (400 
µL per dish) and incubated at 37°C until collagen solidified. RPMI media (2 mL) was 
added and media was replaced the following day, and subsequently every other day. 
Cultures were treated with 0.1% BSA in PBS or 50 ng/mL of TGFα (diluted in 0.1% 
BSA in PBS) on the day of isolation, then the 1 and 3 days following isolation.  
 
2.5 Tissue Fixation and Staining  
Tissues from the body and neck of the pancreata from mice were isolated and fixed in 4% 
paraformaldehyde or Shandon cryomatrix embedding resin (ThermoFisher Scientific) for 
paraffin or cryostat sectioning, respectively. Paraffin sections were embedded following 
rehydration. Paraffin and cryostat samples were sectioned to 5-7 µm using the HM325 
Rotary Microtome (ThermoFisher Scientific) or the Shandon cryostat (ThermoFisher 
Scientific), respectively.  
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Acini embedded in collagen matrices were fixed in cryomatrix after one or three days of 
culture with 4% formaldehyde in PBS overnight. The following day, samples were rinsed 
with PBS 3x 1 hour each, and 5% sucrose solution was added. Samples were incubated 
overnight. Over two subsequent days, samples were transferred to 10% and then 20% 
sucrose solutions. Cells were embedded in Shandon Cryomatrix resin and sectioned to 5-
8 µm using the Shandon cryostat.  
For immunofluorescence (IF) analysis, cryostat tissue sections were fixed in 4% 
formaldehyde in PBS for 10 minutes, then washed 3 x 5 minutes in PBS. Sections were 
permeabilized in 0.1% Triton X-100 in PBS for 10 minutes, followed by 3 x 5 minutes 
PBS washes. Tissue was incubated in blocking solution consisting of 5% BSA in 0.1% 
Triton X-100 in PBS, and incubated at room temperature for 30 minutes. Sections were 
washed with blocking solution 3 x 5 minutes before adding primary antibody diluted in 
blocking solution and incubated at 4°C overnight. The primary antibodies used were ones 
raised against amylase (1:1000; Abcam Inc.). Slides were washed 3 x 5 minutes with PBS 
before adding anti-rabbit fluorescein isothiocyanate (FITC;1:250, Jackson 
ImmunoResearch, West Grove, PA) diluted in blocking solution for 1 hour at room 
temperature. To allow for visualization of nuclei, sections were incubated for 5 minutes 
in 4',6-diamidino-2-phenylindole (DAPI; 1:1000) diluted in dH2O. Slides were washed 3 
x 5 minutes with dH2O and mounted using PermaFluor mounting media (ThermoFisher 
Scientific). Tissue sections were imaged using an Automated Upright Microscope (Leica 
Microscope DM5500B, camera DFC450; Leica Microsystems, Wetzlar, Germany) and 
LAS V4.4 software (Leica Microsystems).  
38 
 
For immunohistochemical (IHC) analysis, paraffin slides were dehydrated through a 
xylene/ethanol series and then immersed in working solution (0.1 M Citric Acid 
Monohydrate, 0.1 M sodium citrate dehydrate in dH2O) and boiled for 45 minutes for 
antigen retrieval. Sections were cooled to room temperature (~20 minutes). Tissue was 
processed using the Immunocruz Rabbit ABC Staining System (Santa Cruz, Dallas, TX). 
Briefly, sections were incubated in a methanol, hydrogen peroxide solution for 10 
minutes, permeabilized in 0.2% Triton X-100 in PBS for 12 minutes, then washed with 
0.2% Tween-20 in PBS for 5 minutes. Sections were incubated in blocking solution (5% 
rabbit serum and PBS) for 1 h before incubating in primary antibody raised against SOX9 
(1:500, diluted in blocking solution, Abcam Inc., Cambridge, United Kingdom) overnight 
at 4°C. The following day, sections were rinsed with 0.2% Tween-20 in PBS for 6 
minutes, followed by 4 x 6 minutes PBS washes. Sections were then incubated at room 
temperature for 30 minutes with biotinylated mouse anti-rabbit IgG secondary antibody 
(diluted 1:1000 as per manufacturer’s instructions) (Sigma). Sections were washed for 6 
minutes with 0.2% Tween-20 in PBS, then 2 x 6 minutes with PBS. Sections were 
incubated for 30 minutes in AB enzyme reagent (avidin, biotinylated HRP, PBS), 
prepared as per Immunocruz Rabbit ABC staining system directions. Sections were 
washed 3 x 6 minutes each with PBS, incubated in Peroxidase substrate for 6-20 minutes, 
until nuclei staining was visible on positive controls. Sections were washed 3 x 5 minutes 
in dH2O, then counterstained with hematoxylin for 1 minute, followed by dehydration 
through ethanol/xylene.  
For histological examination of tissues, sections were stained with hematoxylin and eosin 
(H&E) and Masson’s Trichrome. For paraffin tissue sections, slides were deparaffinized 
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in xylene 3 x 5 minutes, then rehydrated through ethanol and dH2O. For frozen cell 
sections, the previous steps were omitted, and slides were placed directly into 70% 
ethanol for 2 minutes. Slides were then stained with H&E. Tissue was subsequently 
dehydrated in 90% ethanol for 1 minute, then 100% ethanol 2x for 3 minutes, before 
being placed in xylene 3x for 5 minutes. Paraffin tissue sections were stained for 
Masson’s Trichrome using kit instructions. Following staining, slides were mounted 
using Permount and imaged using an Automated Upright Microscope (Leica Microscope 
DM5500B, camera DFC450 FX) and LAS V4.4 software (Leica Microsystems).  
2.6 Cyst, Cell Thickness and Lesion Area Quantification 
To assess acinar-to-duct cell metaplasia in culture, acinar cell clusters were visually 
assessed on days 1 and 3 following isolation using an inverted, phase-contrast 
microscope (Leica DMIL). Culture in 3D collagen matrix allows for cysts to develop in 
multiple planes of focus. For these in vitro studies, I established a set of criteria to 
identify ADM structures: i) a lumen had to appear in a cluster of acinar cells, ii) be 
visible in multiple planes of focus, iii) and appear with flattened cellular structures 
surrounding it. To capture the entirety of the plate, 50 acinar cell clusters were counted, 
and ADM quantified.  
Cell thickness, of acinar cells that make up putative ADM in TGFα-treated cultures, was 
analyzed on paraffin sections stained with H&E, and assessed using ImageJ software. 
Cell thickness was determined according to the width of the nuclei surrounding the 
perimeter of putative ADM. Nuclei were measured at 3 distinct, evenly spaced points 
around the structure (Appendix 1). An average of 3 measurements per cyst were 
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calculated, for 1-6 cysts per genotype on days 1 or 3 of culture. Data presented is the 
average of three wild type and three Atf3-/- mice. 
To assess the degree of damage and inflammation present in pancreatic tissue, H&E 
slides were imaged using the Aperio CS2 Digital Scanner and Aperio Imagescope 
Software (Leico Biosystems Imaging Inc.) Images were then analyzed using ImageJ 
(National Institutes of Health, Maryland, USA) software to determine the area of damage 
and inflammation (lesion area) relative to total tissue area.  
2.7 Statistical Analysis 
Differences between experimental groups for cell culture analysis, as well as body weight 
analysis for the chronic pancreatitis experiment were compared using a repeated 
measures two-way ANOVA, followed by Tukey’s post hoc test. QRT-PCR results were 
analyzed using an unpaired t-test, with the exception of Rbpj/Rbpjl ratio, which were 
analyzed by two-way ANOVA, followed by Tukey’s post hoc test. Western blots and 
lesion area quantification were analyzed by an unpaired t-test. Significance is considered 
a P-value <0.05.  
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Chapter 3  
3 Results 
3.1 Atf3 promotes gene expression changes indicative of 
ADM development 
Previous work suggested that loss of ATF3 resulted in reduced ADM in vivo (Fazio et al., 
2017). To determine the underlying mechanisms, congenic wild-type (Atf3+/+) and Atf3-/- 
mice were treated with cerulein, and analyzed 4 and 72 hours after initial injections. 
Expression of RBPJ and RBPJL, both of which compete for binding to the PTF1A 
complex, were assessed as markers of a de-differentiated (progenitor-like) and 
differentiated (acinar) phenotype, respectively. At 4 hours post-CIP, Rbpj mRNA levels 
were significantly increased in pancreatic tissue of wild-type mice (2.16±0.34 fold), 
while Rbpjl mRNA levels was not statistically different (p>0.05) compared to saline. 
Conversely, pancreatic tissue from Atf3-/- mice showed no changes in either Rbpj or Rbpjl 
mRNA levels at 4 hours post-CIP (p>0.05; Figure 3.1A). At 72 hours post-CIP, mRNA 
levels of Rbpj remained significantly higher in CIP-treated wild-type mice (6.04±1.01 
fold), while Rbpjl was unchanged from saline-treated controls. Similar comparisons in 
Atf3-/- mice at 72 hours post-CIP revealed significantly increased Rbpj mRNA levels 
(3.74±0.80 fold), with no changes in Rbpjl mRNA levels compared to saline-treated 
controls (p>0.05; Figure 3.1A). Since RBPJ and RBPJL compete for PTF1A, we 
examined the ratio of the mRNA levels of the two genes following CIP (Masui et al., 
2010). At 4 hours post-CIP, the ratio of Rbpj/Rbpjl was significantly increased in both 
wild-type and Atf3-/- mice when compared to saline treatment  
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Figure 3.1 Atf3-/- mice show altered ratios of Rbpj and Rbpjl gene expression during 
acute CIP. (A) QRT-PCR analysis of Rbpj and Rbpjl expression in pancreatic tissue 
from wild type and Atf3-/- mice at 4 and 72 hours following saline (SAL) or cerulein (CIP) 
treatment. Rbpj expression was significantly increased in wild-type mice at both 4 and 72 
hours post-CIP compared to saline, while in Atf3-/- mice, Rbpj was only elevated at 72 
hours post-CIP compared to saline (*p<0.05). Rbpjl expression was not statistically 
different compared to saline for either genotypes at 4 or 72 hours post CIP (p>0.05). (B) 
When assessed as a ratio of Rbpj to Rbpjl, both relative to Mrpl, Rbpj/Rbpjl expression 
was significantly increased in wild type and Atf3-/- 4 hours post-CIP compared to saline, 
and only in wild-type tissue 72 hours post-CIP compared to saline (ap<0.05; n=4-6). 
Mean±SEM is shown. 
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(p<0.0001). This effect was maintained in wild-type mice at 72 hours, where CIP-treated 
mice showed a significantly increased ratio compared to all groups. In contrast, no 
changes were detected in the ratio of Rbpj/Rbpjl in Atf3-/- mice at 72 hours post CIP 
(p<0.0001; Figure 3.1B). This suggests loss of Atf3 does not alter progenitor mRNA 
levels to affect the ADM phenotype.  
I next assessed expression of Nr5a2, a marker of acinar cell maturation. In wild-type 
mice, expression of Nr5a2 was significantly decreased 4 hours following CIP treatment 
(0.68±0.05 fold), but was not significantly different 72 hours following treatment 
(p>0.05; Figure 3.2) compared to saline-treated mice. Comparatively, Nr5a2 expression 
was not different in Atf3-/- mice at either time point, suggesting ATF3 may not be 
targeting Nr5a2 expression following initial injury (p>0.05).  
MRNA levels of genes that represent a progenitor-like phenotype, and are re-activated 
during ADM, were assessed by qRT-PCR analysis. Pdx1 exhibited no changes in 
expression following CIP at either time point in both genotypes (Figure 3.3A). 
Conversely Sox9 expression was significantly increased in pancreatic tissue from wild-
type mice at both 4 (6.17±1.23 fold) and 72 hours (4.95±0.85 fold) following CIP 
(Figure 3.3B) compared to saline. Similar analysis in pancreatic tissue from Atf3-/- mice 
revealed a significant increase in Sox9 expression only at 4 hours (2.41±0.28 fold) 
following injury, but not at 72 hours post CIP (p>0.05). These results suggested that 
ATF3 may be required for increased Sox9 expression and increased progenitor gene 
expression during ADM.  
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Figure 3.2 Wild type mice show decreased Nr5a2 expression during acute CIP. QRT-
PCR analysis of Nr5a2 expression 4 and 72 hours after saline (SAL) and cerulein (CIP) 
treatment. Nr5a2 was significantly decreased 4 hours post-CIP in wild-type mice 
compared to saline treated mice (*p<0.05), while there was no statistical difference for 
Nr5a2 72 hours post-CIP (n=4-6) compared to saline. No statistical difference was 
observed in Atf3-/- models 4 and 72 hours following CIP compared to saline (n=4-6; 
p<0.05). Mean±SEM is shown.  
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Figure 3.3 Wild type mice show increased gene expression of pancreatic progenitor 
and duct markers at later time points in acute CIP (A) QRT-PCR analysis of Pdx1 
expression at 4 and 72 hours after saline (SAL) or cerulein (CIP) treatment indicated no 
significant difference in wild type and Atf3-/- (p>0.05) compared to saline controls. QRT-
PCR analysis of (B) Sox9 and (C) Krt19 at 4 and 72 hours following CIP. Expression of 
Sox9 and Krt19 was significantly increased in pancreatic tissue at 4 hours post-CIP in 
both wild-type and Atf3-/- compared to saline, however expression remained significantly 
increased at 72 hours compared to saline in only CIP-treated wild-type mice (*p<0.05; 
n=4-6). Mean±SEM is shown. 
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To assess the effect of Atf3 on the expression of a specific duct cell marker, qRT-PCR 
was performed for Krt19 (Figure 3.3.C). Expression of Krt19 was significantly increased 
in wild-type mice following CIP at both time points (4 hours, 6.29±0.46 fold; 72 hours, 
4.30±1.81 fold) compared to saline (Figure 3.3C). However, Krt19 expression was only 
increased in Atf3-/- CIP-treated mice at 4 hours (2.94±0.15 fold), and not at 72 hours post 
CIP (p>0.05), suggesting ATF3 was required for ductal marker expression. Alternatively, 
ATF3 may be responsible for promotion of a progenitor phenotype, thereby allowing 
ductal differentiation to occur. To confirm that SOX9 expression was specific to ADM, I 
performed IHC and showed that 72 hours following injury, SOX9 accumulated in 
lesioned areas (pancreatic tissue with damage and evidence of ADM) in wild-type mice 
(Figure 3.4). While some SOX9 expression was observed in pancreatic tissue from Atf3-/- 
mice, this accumulation of SOX9 was reduced compared to wild type CIP-treated models 
and found mostly in putative acinar cells (Figure 3.4).  
Signaling through the EGFR pathway is required for ADM development (Ardito et al., 
2012; Eser et al., 2014). To determine if ATF3 was promoting ADM development by 
affecting EGFR signaling, mRNA expression of Egfr and a downstream regulator of the 
pathway, Mek1, was assessed (Figure 3.5A). Egfr expression was significantly increased 
in pancreatic tissue from wild-type mice at both 4 (8.27±0.66 fold) and 72 (6.29±0.93 
fold) hours following CIP compared to saline, while Atf3-/- mice showed increased Egfr 
expression only 4 hours following CIP compared to saline (4.66±1.03 fold) (Figure 
3.5A). Increased Mek1 expression is observed 4 (1.94±0.18 fold) and 72 (5.86±1.27 fold) 
hours following injury in wild-type mice compared to saline, but not at either time point 
in Atf3-/- mice (p>0.05; Figure 3.5B). Analysis of EGFR ligands 4 hours post-CIP shows  
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Figure 3.4 SOX9 accumulation occurs in ADM lesions in wild type pancreatic tissue. 
(A) Immunohistochemical analysis for SOX9, a pancreatic progenitor marker, shows 
more positive staining of SOX9+ cells (white arrows) in wild-type tissue following CIP 
relative to tissue from Atf3-/- mice at the same time point. White arrowheads indicate no 
SOX9 expression. Black boxes indicate regions of higher magnification. Scale bars = 50 
µm.  
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Figure 3.5 Absence of ATF3 affects mRNA levels of EGFR signalling pathway 
members and ligands during acute CIP. QRT-PCR analysis of EGFR pathway 
members (A) Egfr and (B) Mek1 following saline (SAL) or cerulein (CIP) treatment. 
Increased expression of Egfr compared to saline was detected at both 4 and 72 hours 
post-CIP in pancreatic tissue of wild-type mice. Atf3-/- mice show significantly increased 
expression of Egfr at 4 hours, but not 72 hours (p>0.05), post-CIP compared to saline. 
Mek1 expression is significantly increased at 4 and 72 hours following injury in wild-type 
mice (p<0.05), with no statistically difference in Mek1 expression in Atf3-/- mice post-CIP 
at either time point compared to saline (p>0.05; n=4-6). (C) QRT-PCR assessment of 
EGFR ligands Egf and Tgfα show significantly decreased expression of Tgfα in both 
wild-type and Atf3-/- mice 4 hours post-CIP compared to saline (p<0.05); however, no 
statistical differences in Egf expression was detected in mice of either genotype following 
CIP at the same time point (p>0.05; n=4-6). Mean±SEM is shown. 
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a significant decrease in Tgfa expression following CIP in both wild-type (0.64±0.05 
fold) and Atf3-/- mice (0.43±0.12 fold) compared to saline; however no significant 
differences following cerulein treatment compared to saline were detected in the 
expression of Egf (p>0.05; Figure 3.5C).  
To see if the changes in mRNA expression were reflective of changes to EGFR pathway 
protein abundance, the ratio of active ERK (pERK) to total ERK was assessed at 4 hours 
post- CIP. pERK/tERK ratio in wild type and Atf3-/- mice was compared relative to saline 
(Figure 3.6A). As insufficient n values did not allow for statistical analysis, comparisons 
were made between only cerulein-treated samples. While the ratio of pERK to tERK 
seemed higher in CIP-treated wild-type mice, the increase was not significant when 
compared to samples from CIP-treated Atf3-/- mice (p>0.05; Figure 3.6B). The variability 
in these findings may reflect the low number of mice included in this analysis (n=3). 
3.2 Atf3-/- acini form morphologically distinct structures 
compared to wild type acini in culture 
During CIP, ATF3 appeared to be required for changes in gene expression that prime 
cells for acinar cell de-differentiation, and promote transdifferentiation to a more duct-
like phenotype. To determine if the ability to undergo ADM is dependent on ATF3 
expression, acinar cells from wild-type and Atf3-/- mice were isolated and treated with 
TGFα, a ligand for EGFR signaling known to be involved in ADM development (Means 
et al., 2005; Shi et al., 2013; Liou et al., 2015). Cultured cells were embedded in 
collagen, either left untreated, treated with a vehicle (BSA) or 50 ng/mL TGFα, and 
followed for 3 days post-isolation (Figure 3.7A). Cysts (putative ADM) were counted for 
a total of 50 acinar clusters per  
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Figure 3.6 Loss of ATF3 does not affect EGFR pathway protein abundance  
(A) Western blot analysis of phosphorylated ERK (pERK) levels relative to total ERK 
(tERK) in pancreatic tissue of wild-type and Atf3-/- mice 4 hours following saline and CIP 
treatment. No statistical analysis was completed due to insufficient n values (n=2).  (B) 
Western blot analysis of pERK levels relative to tERK for only CIP-treated tissue 
indicates no statistical difference in ERK abundance in Atf3-/- tissue relative to wild-type 
tissue (p=0.25; n=3). Mean±SEM is shown. 
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Figure 3.7 Morphology of wild-type and Atf3-/- acini cysts following TGFα 
treatment.  
(A) Representative bright field images for wild-type (WT) and Atf3-/- untreated (unt) 
acini, or acini treated with 0.1% bovine serum albumin (BSA) in PBS or 50 ng/mL TGFα 
and cultured for 1-3 days. Cysts (black arrows) are observed in both WT and Atf3-/- 
TGFα-treated acini by day 2 and 3. Scale bars= 100 µm.  
(B) Quantification of the number of cysts found in 50 acinar cell clusters isolated from 
WT and Atf3-/- mice for untreated, and BSA and TGFα treated cells. Both wild type and 
Atf3-/- cells treated with TGFα produce significantly more cysts than untreated and BSA 
controls (ap>0.05), however no statistical significance is observed between wild-type and 
Atf3-/- cells in any treatment group (n=4). Mean±SEM is shown. 
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treatment group. Untreated and BSA-treated cells formed cysts (putative ADM) in less 
than 20% of the total acinar clusters in cells isolated from both wild-type (unt=10.44 
cysts; BSA=12.11 cysts) and Atf3-/- (unt=10.22 cysts; BSA=11.33 cysts) mice.  
Significantly more cysts formed in wild-type cells (26.56 cysts/50 acinar clusters) treated 
with TGFα (p<0.05) compared to controls. Analysis of cyst formation in Atf3-/- cultures 
showed similar results (25.56 cysts/50 acinar clusters), indicating ATF3 is not necessary 
for TGFα-mediated cyst formation in culture (Figure 3.7B).  
Analysis of the cysts suggested a difference in morphology between wild type and Atf3-/- 
acini. Sections of acinar cell cultures were examined by H&E staining to compare overall 
morphology. At day 3, wild-type acinar clusters treated with TGFα formed putative 
ADM structures that showed a squamous (thin and flattened)-cell like morphology 
(Figure 3.8A). Conversely, Atf3-/- cultures did form cyst structures, but were less 
squamous-cell like, as the perimeter of the acinar cell, and the nuclei within it, were not 
elongated as seen in wild type cells. Quantitatively, at day 3 in culture, ADM structures 
from wild-type pancreatic tissue had significantly thinner cells (6.19 ± 0.50 µm vs. 9.22 ± 
0.41 µm) composing the perimeter, indicating a more squamous-cell phenotype relative 
to Atf3-/- cysts which had thicker cells composing the perimeter (p<0.05; Figure 3.8B). 
Cell thickness alone does not indicate whether ADM that forms between these two 
genotypes are phenotypically different. Therefore it was necessary to stain for a mature 
acinar cell marker. BSA and TGFα-treated acinar cells from wild-type and Atf3-/- mice 
were stained against amylase by immunofluorescence. Positive amylase staining was  
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Figure 3.8 Atf3-/- acini form morphologically distinct cysts from wild-type acini.  
(A) Representative H&E staining of untreated (unt), and BSA and TGFα treated wild-
type (WT) and Atf3-/- acini cultured for 1-3 days. Cysts (black arrows) are observed in 
both WT and Atf3-/- TGFα-treated acini by day 3. Scale bars = 100 µm. (B) Quantification 
of cell thickness in cysts of TGFα-treated acinar cells on days 1 and 3. By day 3, wild-
type acinar cells have significantly thinner cells around the perimeter of the cyst, 
indicating a more squamous-like phenotype (ap<0.05; n=1-6 cysts per treatment 
condition. This was repeated for 3 wild-type and 3 Atf3-/- mice). Mean±SEM is shown. 
 
 
 
 
 
 
60 
 
observed in wild-type cells at day 1, while decreased staining was observed diminished 
by day 3 following TGFα treatment. Similar analysis of Atf3-/- cultures showed positive 
amylase staining at day 1 that was maintained on day 3, including following TGFα 
treatment. This suggests that while ADM-like structures were present in Atf3-/- cultures, 
these cells did not lose a mature acinar differentiation status (Figure 3.9).  
3.3 Atf3-/- mice show decreased severity of acinar tissue 
damage in response to recurrent pancreatic injury 
Findings thus far suggested that absence of Atf3 altered the ADM process both in vivo 
following acute injury, and ex vivo in culture. These results suggested that loss of ATF3 
would affect the response to chronic or recurrent pancreatic injury, which is a significant 
risk factor to PDAC (Yadav et al., 2011). To examine this, congenic wild-type (Atf3+/+) 
and Atf3-/- mice were exposed to recurrent saline (vehicle control) or cerulein I.P 
injections (250 µg/kg) twice daily for 14 days and allowed to recover 7 days following 
the last injection. Body weights were measured throughout the experimental time period, 
and at 3 and 7 days following the last injection. Wild-type CIP-treated mice showed 
significant decreases in body weight compared to wild-type saline mice from days 8 to 
17, before weight was restored by day 21 (p<0.05; Figure 3.10). Similar analysis in  
Atf3-/- mice did not reveal significant decreases in body weight relative to wild type saline 
treated mice.  
To assess tissue damage, saline and CIP-treated pancreatic tissues were assessed by 
histology 7 days following cessation of CIP.  H&E staining demonstrated increased 
fibrosis and inflammatory infiltration in wild-type CIP-treated mice compared to Atf3-/-  
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Figure 3.9 Atf3-/- acini maintain amylase expression in cyst structures. 
Immunofluorescence staining for amylase in BSA and TGFα-treated wild-type and Atf3-/- 
primary acinar cells. Amylase staining is observed in BSA and TGFα-treated cells at day 
1 (arrows). Staining is mostly absent in wild-type TGFα-treated cells by day 3 (arrow 
heads), but remained detectable in Atf3-/- acini (arrows) suggesting maintenance of the 
acinar phenotype in Atf3-/- cells (n=3). Scale bars = 25 µm. 
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Figure 3.10 Wild-type mice show decreased body weight during recurrent 
pancreatitis. Chronic pancreatic injury was induced in wild-type (WT) and Atf3-/- mice 
by recurrent cerulein (CIP) injections (250 µg/kg body weight) twice daily for 14 days. 
Mice recovered for 7 days before sacrifice. Analysis of body weights over the injection 
period, as well as 3 and 7 days following cessation of CIP, indicates that presence of 
ATF3 during injury significantly decreases body weight from days 8 to 17 before weight 
restoration at day 21 (*p<0.05; n=5). Mean±SEM is shown. 
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Figure 3.11 Recurrent pancreatic injury leads to damage in wild-type mice relative 
to Atf3-/- mice. (A) Representative H&E histology of pancreatic tissue following chronic 
CIP-induced injury in wild-type and Atf3-/- mice. Saline treated mice show no damage in 
response to treatment. Cerulein (CIP) treatment induced more damage (as evident by 
increased ADM and inflammation) in wild-type pancreata compared to Atf3-/- CIP 
models. Black boxes indicate regions of higher magnification. Black scale bars = 100 µm. 
White scale bars = 50 µm. Representative of n=5. (B) Quantification for areas of damage 
and inflammation following chronic injury indicates significantly more lesion area 
relative to total tissue area following CIP treatment in both wild type and  
Atf3-/- compared to saline (ap>0.05), but no significant difference is observed between 
wild type and Atf3-/- CIP treated samples (n=5). Mean±SEM is shown. 
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CIP-treated mice (Figure 3.11A). Lesion area (areas of damage and ADM) were assessed 
relative to total tissue area in wild type and Atf3-/- saline and CIP treated mice. While 
there was a significant increase in percent lesion area in both the wild type and Atf3-/- CIP 
models compared to saline (p>0.05), there was no significant different in lesion area 
between CIP treated samples (Figure 3.11B). 
To provide further qualitative analysis of damage, trichrome staining was conducted on 
histological sections of pancreas tissues from wild-type and Atf3-/- mice following chronic 
injury to assess tissue fibrosis. While damage is increased following CIP treatment in 
both genotypes, no overt differences in fibrosis were observed between wild-type and 
Atf3-/- mice (Figure 3.12).  
To determine if acinar cell de-differentiation was contributing to increased pancreatic 
tissue damage observed histologically, amylase protein levels were assessed by western 
blot. When analyzing individual samples, it appeared the majority of mice showed 
decreased amylase expression following chronic CIP treatment compared to saline, 
however no statistical significance was observed in both wild type and Atf3-/- mice 
(p>0.05; Figure 3.13).  
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Figure 3.12 No differences in tissue fibrosis following chronic injury in wild type 
and Atf3-/- . Representative Masson’s trichrome staining following chronic pancreatic 
injury in wild type and Atf3-/- mice. Cerulein treatment (CIP) increases damage relative to 
saline models (white arrows), however no differences in fibrotic tissue accumulation are 
observed between wild type and Atf3-/- CIP treated mice. Black boxes indicate regions of 
higher magnification Black scale bars = 100 µm. White scale bars = 50 µm. 
Representative of n=5. Mean±SEM is shown. 
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Figure 3.13 Cerulein treatment does not affect amylase expression in wild type and  
Atf3-/-. (A) Representative western blot analysis of amylase protein levels in pancreatic 
tissues 7 days following cessation of saline (SAL) or chronic cerulein (CIP). (B) 
Densitometry analysis of amylase relative to tERK following chronic injury indicates no 
statistical difference compared to saline in either wild type or Atf3-/- models  (p>0.05; 
n=5). Mean±SEM is shown. 
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Chapter 4  
4 Discussion and Conclusions 
4.1 Overview 
During acute pancreatic injury, acinar cells undergo de-differentiation as a protective 
mechanism to reduce further damage (Jensen et al., 2005; Karki et al., 2015). This de-
differentiation process into a progenitor-like phenotype allows for regeneration of 
damaged cells, and repopulation of the exocrine pancreas (Murtaugh & Keefe, 2015; 
Karki et al., 2015). In murine models with acute episodes of injury, complete 
regeneration occurs within 7 days (Grady et al., 1998; Yadav et al., 2011). However, if 
the cells are exposed to a continuous insult, the de-differentiation process becomes fixed, 
and cells cannot re-differentiate, therefore undergoing ADM (Logsdon & Ji., 2009; 
Morris et al., 2010). In this thesis, I show that ATF3 represses the acinar differentiation 
program at early time points following injury, and is required to maintain gene expression 
changes 72 hours following injury, when regeneration is occurring. Not only does ATF3 
affect mRNA levels of genes required for mature acinar cell differentiation, but it also 
affects ADM-promoting pathways such as EGFR. Loss of Atf3 reduced expression of 
EGFR pathway regulators (Egfr, Mek1) following injury relative to saline, which may 
explain the reduced damage, and decreased formation of ADM in primary acinar cultures 
that are evident in the absence of Atf3.  
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Patients with chronic pancreatitis are more susceptible to developing PDAC; therefore 
exploring Atf3 following chronic insult was necessary (Yadav & Lowenfels, 2013). Loss 
of Atf3 resulted in decreased inflammatory infiltration and damage following chronic 
injury. These findings provide evidence that ATF3 directs ADM development and 
worsens the pancreatic phenotype following injury. However, it is still important to 
determine whether Atf3 is contributing to this worsened phenotype by increasing damage, 
or preventing the regenerative program.  
4.2 ATF3 targets transcription factors required for ADM 
Previous studies from our lab showed that following acute pancreatic injury, the loss of 
Atf3 initially caused a worsened phenotype, with increased damage and fibrosis (Fazio et 
al., 2017). However, when comparing degree of regeneration at a later time point (72 
hours), loss of Atf3 promoted increased healthy acinar tissue and reduced incidences of 
damage, while wild-type mice showed increased ADM. The phenotypic changes that 
were evident histologically are explained by how the differentiation program is affected 
by insult. Atf3 contributes to repression of the differentiation program through decreased 
expression of Rbpjl and Nr5a2 (Figure 3.1A; Figure 3.2). It is difficult to conclude 
whether the decreases in expression that are observed are due to direct ATF3-mediated 
transcriptional regulation. It may be that Atf3 is re-activating the progenitor program, as 
seen through increases in expression of Sox9 (Figure 3.3), and that these cells decrease 
mature transcription factor expression because they are de-differentiating. However, 
recently published data from our lab suggests that ATF3 is directly affecting the mature 
acinar phenotype by repression of Nr5a2, Rbpjl, and Mist1 gene expression (Fazio et al., 
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2017). ChIP sequencing data suggests that Atf3 accumulates on the promoter regions of 
Nr5a2 and Rbpjl, suggesting an influence on the transcriptional programs that maintain 
differentiated acinar cells. To conclusively demonstrate whether Atf3 is affecting 
transcription of these genes, determining what other proteins are binding with ATF3 to 
the DNA is necessary. ATF3 can repress transcriptional programs by recruitment of 
inhibitory HDACs to gene promoters (Kwon et al., 2015). In line with this result, we 
have shown that ATF3 recruits HDAC5 to the Mist1 promoter, leading to repression, and 
therefore downregulation of the mature acinar phenotype (Fazio et al., 2017). Therefore, 
ATF3 may be functioning in a similar manner to decrease expression of Nr5a2 and Rbpjl.  
As stated previously, it cannot be excluded that ATF3 directly upregulates the progenitor 
and duct programs to promote ADM. Results from previous ChIP sequencing data 
suggested that ATF3 increased expression of Sox9 and Krt19 through direct binding to 
promoter regions (Fazio et al., 2017). There is also evidence that ATF3 binds to and 
represses expression of other pancreatic progenitor markers, such as Pdx1 in β-cells (Jang 
et al., 2001). This study showed that ATF3 could directly bind to promoters of pancreatic 
progenitor factors. In acinar cells, we would expect ATF3 to promote progenitor gene 
expression rather than repress progenitor gene expression as it does in β-cells. The 
difference in ATF3’s mechanism of action in β-cells compared to acinar cells may be due 
to additional proteins, bound along with ATF3 in a transcriptional complex, that are 
responsible for directing a decrease in expression. The mechanism by which ATF3 can 
cause activation or repression of these factors remains to be determined. Since it is 
known that ATF3 can regulate expression of progenitor genes (Jang, 2011), exploring 
how ATF3 regulates expression of other progenitor and ductal cell factors, such as Sox9 
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and Krt19, will allow us to determine if Atf3 is responsible for activating transcription of 
these factors. While changes to Krt19 expression may be secondary to ATF3’s effects, as 
Sox9 can increase expression of this ductal marker (Murtaugh & Keefe, 2015), it is still 
worth exploring the transcriptional complexes that ATF3 is a part of which increase 
progenitor and ductal expression.  
In addition to the role that ATF3 plays in regulating the acinar transcriptional program, it 
may also be forcing ADM through increased EGFR signalling, a known driver of ADM. 
Activation of EGFR by EGF and TGFα ligands has been shown in both in vitro and in 
vivo pancreatic injury models (Sandgren et al., 1990; Means et al., 2005). In murine 
models, upregulation of EGFR signalling through increased TGFα expression by a 
metallothionein-promoter indicates the necessity of this pathway in initiating ADM, and 
progressing to PDAC (Sandgren et al., 1990). As well, these changes are an acinar-
specific event, as isolated primary pancreatic acinar cells show transformation to a ductal 
phenotype upon treatment with TGFα (Means et al., 2005). Previous work in our lab has 
shown that ATF3 has an effect on EGFR signalling, as Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway analysis following RNA-sequencing shows that loss of ATF3 
downregulates the expression of genes associated with EGF signalling following injury 
(Fazio et al., 2017). This is reflected by qRT-PCR analysis, which shows that Egfr is 
elevated in wild type and Atf3-/- models 4 hours following acute injury relative to saline, 
but remains elevated at 72 hours in only wild type models (Figure 3.5A). Since 
overexpression of EGFR is implicated in human PDAC cases (Fitzgerald et al., 2015), it 
may be that ATF3 is initiating transcription of Egfr and Mek1, leading to overexpression 
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of these pathways, and potentially increased activation and ADM. The loss of Atf3 may 
then be protective against EGFR-induced ADM, as it decreases transcription of EGFR. 
ATF3 may also affect the EGFR pathway further downstream. Phosphorylated ERK 
proteins are responsible for activating transcription of various factors required to induce 
cell functions such as cell survival or proliferation. ERK has been implicated in activating 
transcription of NFκB and JUN (Chang et al., 2003; Molina & Adjei, 2006; Roberts & 
Der, 2007), both proteins which are implicated in ATF3 signalling (Jiang et al., 2004; 
Liang et al., 2006; Kwon et al., 2015). Therefore, pERK may be functioning as a 
feedback mechanism to further induce ATF3 transcription, which can then act together 
with NFkB and JUN to induce inflammation and proliferation, and therefore promote 
ADM. Analysis of this possibility would need to be explored further. A limitation to the 
current analysis is a lack of significance in pERK levels between genotypes due to 
insufficient n values (Figure 3.6B). I show that there may be association between EGFR-
related genes (Egfr and Mek1) and ERK pathway activation, however to show that ERK 
activation is a direct result of EGFR signalling needs to be elucidated. Repeating this 
experiment with increased mice may provide more definitive data.   
While the effects of ATF3 on EGFR-mediated ADM have been investigated in this study, 
to truly understand whether ATF3 is responsible for ADM, it would be necessary to 
analyze the effects of ATF3 on other ADM-promoting signalling pathways, such as 
Notch signaling. In combination with additional PDAC driving mutations, such as 
KRAS, Notch signaling accelerates the reprogramming process (Morris et al., 2010). 
This indicates that differential expression of multiple developmental signalling pathways 
is implicated in cancer progression. Loss of ATF3 may therefore be not only decreasing 
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ADM through EGFR signalling, but through repression of inappropriately re-activated 
notch signalling. Analysis of downstream factors of Notch signalling between wild-type 
and Atf3-/- mouse tissue would elucidate this possibility.  
4.3 ADM formation in primary acinar cells is affected by the 
loss of ATF3 
The necessity of ATF3 as a driver of the ADM process was analyzed through primary 
acinar cultures. Treatment of wild-type and Atf3-/- acinar cells with TGFα forced acinar 
cell de-differentiation into cyst, tubular structures representative of ADMs (Figure 3.7). 
Interestingly, loss of ATF3 did not lead to decreased cyst formation as predicted. 
However, the structures that formed were not indicative of ADM, as these cells 
maintained expression of the mature acinar marker amylase. Differences in cyst 
formation may not have been observed due to overactive EGFR signalling in both wild 
type and Atf3-/-. As overexpression of EGFR activates ADM (Fitzgerald et al., 2015), it 
may be that the Atf3-/- acinar cultures were treated with a high concentration of TGFα, 
and that despite decreases in Egfr and Mek1 expression implicated with a loss of Atf3 
(Figure 3.4), activation of this pathway was still able to initiate the ADM process. 
However, phenotypic ADMs did not form in Atf3-/- cultures, as these cells maintained an 
acinar phenotype, indicating there still is differential pathway activation (Figure 3.9). 
These cultures were only analyzed up to a 3 day time point. It is known that cyst 
structures of true ADMs are able to survive in culture for up to 14 days (Means et al., 
2005). Therefore, these cultures should be analyzed at time points beyond what I have 
documented in this study. I would predict that Atf3-/- cysts would undergo apoptosis if 
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followed beyond a 3-day time point, while the wild type ADMs persist in culture for days 
following.  
To determine the extent of how ATF3 affects ADM, additional pancreatic enzymes and 
markers of a mature acinar phenotype should be examined, such as β-catenin. It has been 
previously shown that maintenance of β-catenin signalling is necessary for blocking 
ADM, and is an important predictor of acinar cell fate and PDAC development (Morris et 
al., 2010). If the loss of Atf3 leads to maintained β-catenin, as indicated in our previous in 
vivo work (Fazio et al., accepted), it provides further validation to the prediction that Atf3 
is implicated in ADM.  
4.4 Increased damage in wild-type mice may be predictive 
of decreased ability to regenerate following injury 
Chronic pancreatitis increases susceptibility to PDAC development (Yadav & Lowenfels, 
2013). As ADM is a known precursor to PDAC development (Logsdon & Ji, 2009), 
identifying the role of ATF3 in mediating ADM following chronic injury is necessary. 
Our data shows that loss of ATF3 prevents loss of body weight from days 8 to 14 of 
injury, and up to 3 days into recovery (Figure 3.10). This suggests that ATF3 may 
contribute to increased pancreatic damage. As is evident histologically, loss of Atf3 
reduced inflammatory infiltration and damage, and decreased ADM. These assessments 
were completed 7 days following the final injection of cerulein. At the cessation of 
injury, pancreatic acinar cells will attempt to repair damage and undergo regeneration 
(Murtaugh & Keefe, 2015). Evidence of increased and maintained damage in wild-type 
mice during the regenerative period following chronic injury is of particular interest. This 
raises the question as to whether ATF3 expression contributes to increased ADM through 
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increasing damage, potentially through increased inflammation, or is blocking the 
regenerative process.  
Increased damage observed with ADM is typically caused by an increased inflammatory 
response. Following injury, macrophages infiltrate the tissue immediately to try and 
mediate a tissue repair process (Deschênes-Simard et al., 2013). However, continuous 
exposure to injury, such as chronic pancreatitis, will alter the immune program, and lead 
to pathogenic inflammatory injury. Loss of ATF3 may be decreasing the damage 
following chronic pancreatitis through its effects on NFκB. Interactions between ATF3 
and NFκB inhibited inflammatory activity and reduced damage following acute kidney 
injury (Li et al., 2010; Kwon et al., 2015). It may be that in the case of chronic pancreatic 
injury, ATF3 interacts with a different transcriptional complex to instead activate NFκB, 
and promote the inflammatory response leading to increased damage. Another possibility 
is that loss of ATF3 decreases the damage phenotype by promoting a more differentiated, 
mature acinar phenotype, and therefore blocking inflammation and ADM. Previous 
results from our lab have shown that ATF3 represses Mist1, a factor known to reduce 
pancreatic defects and ADM following exposure to injury (Kowalik et al., 2007; Karki et 
al., 2015) . Along with decreased expression in Nr5a2 (Figure 3.2), the loss of these pro-
differentiation factors will sensitize acinar tissue to injury and allow for inflammation to 
persist, and can therefore activate fibrosis via pancreatic stellate cell activation (Murtaugh 
& Keefe, 2015). The potential that loss of ATF3 following chronic injury is protecting 
against increased damage would need to be investigated further.  
An alternative possibility is that decreased damage is observed with the loss of ATF3 
because of the ability of these cells to regenerate to a greater degree. Wild-type mice 
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show increased ADM following chronic injury, while the absence of ATF3 leads to a 
greater accumulation of healthy acinar tissue (Figure 3.11). The inability of wild-type 
acinar cells to regenerate may be because of ATF3’s effects on signalling pathways 
required for regeneration to occur. Studies have shown that following injury, acinar cells 
are replaced by expansion of residual surviving cells, rather than neogenesis from a stem 
cell population (Murtaugh & Keefe, 2015). Regeneration is driven by the Notch 
signalling pathway (Siveke et al., 2008; Murtaugh & Keefe, 2015). The Notch pathway is 
normally activated during embryonic development and regulates exocrine cell fate. 
However, it is expressed at low levels in adult pancreatic tissue, and only becomes re-
activated during the regenerative phase of pancreatitis. Notch signalling will increase 
expression of RBPJ, driving acinar cell progenitor formation and decreasing ductal and 
islet differentiation. Maintenance of notch signalling for extended periods leads to 
inhibition of PTF1A-mediated acinar genes, such as Mist1 and Nr5a2, and leads to 
decreased differentiation (Stanger & Hebrok, 2013; von Figura et al., 2014; Karki et al., 
2015). ATF3 may be acting on Notch signalling to maintain its activation, allowing 
acinar cells to de-differentiate, in an attempt to undergo regeneration, but not re-
differentiate to repopulate damaged areas. Increased notch signalling by ATF3 may 
therefore be sensitizing acinar cells to oncogenic transformation and promote ADM. 
Evidence of this occurring is clear in our in vivo genetic analysis following acute injury, 
as loss of Atf3 shows a decreased ratio of Rbpj/Rbpjl expression following acute 
pancreatitis (Figure 3.1B). In addition to Notch activation, Nr5a2 is required for normal 
acinar regeneration as this transcription factor drives terminal differentiation. Since Atf3 
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is implicated in decreasing expression of this factor (Figure 3.2), it may also be 
repressing regeneration by this mechanism.  
The absence of Atf3 following acute pancreatic injury also decreases expression of factors 
implicated in the EGFR pathway (Egfr and Mek1), and therefore may also be promoting 
regeneration by repressing ADM formation mediated by EGFR. ATF3 may be increasing 
damage following chronic CIP through maintenance of re-activated notch signalling, and 
increased EGFR activation. To confirm this, further experiments analyzing ATF3s effects 
on notch signalling, are necessary. Analysis of notch-activating ligands, Jagged-1,-2, and 
Delta-1 can be assessed to determine if there are differences between genotypes (Su et 
al., 2006).  
In acute models of ADM, we see that loss of ATF3 initially leads to increased damage, 
however these mice are able to recover to a greater extent compared to the wild-type. 
Based on these results, we would predict that with chronic pancreatitis, a loss of ATF3 
would result in worse damage initially, but that these mice would recover quicker. In 
order to truly test this hypothesis, the recurrent injury experiment would be repeated with 
a cohort of mice assessed immediately following injury cessation to assess the differences 
in damage.  
This study included limitations of both the in-vivo and in-vitro work. Due to insufficient 
n values for acute pancreatic mouse studies, differences between genders could not be 
assessed. Repeating these experiments with increased n values, and an even group of both 
male and female mice will allow for this analysis. Difficulties in culturing primary acinar 
cells beyond 3 days provided limitations to the in-vitro work. Assessment of cyst 
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development and potential cyst size differences between wild type and Atf3-/- cells could 
not be completed since primary acinar cells were not viable beyond 3 days-post isolation. 
Alterations to the acinar isolation protocol will perhaps increase viability of these cells 
and allow for extended analysis. Additionally, we cannot conclude that the pancreatic 
phenotype we observe is not due to the loss of ATF3 in pancreatic stellate cells and 
macrophages. Development of a pancreas specific ATF3 knock-out will eliminate the 
potential of these off-target effects.  
4.5 Future Directions and Conclusions 
To establish the mechanism by which Atf3 is regulating genetic expression of acinar, 
progenitor, and duct factors, further analysis must be performed. Determining other 
transcriptional targets that are bound with Atf3 in a transcriptional complex will elude to 
the roles it plays to either activate or repress transcription. Performing co-
immunoprecipitation assays will allow for resolution of co-binding activating or 
repressing factors. Understanding these complexes will allow for a more targeted 
approach to reduce ADM formation.  
The role that Atf3 plays in the EGFR signalling pathway has been minimally explored. To 
fully understand why loss of Atf3 still resulted in cyst formation, treatment of acinar 
cultures with varying concentrations of TGFα is important. It will be necessary to 
perform a concentration gradient of TGFα, and then analyze EGFR activation in both 
wild type and Atf3-/- primary cultures. Repeating treatment with the newly determined 
concentrations and assessing cyst formation for days following treatment will provide a 
greater insight into this process. To further provide support to ATF3’s role in EGFR 
signalling, ADM, and finally PDAC formation, introducing a loss of Atf3 with a mutated 
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KRAS gene is necessary. Currently, mouse lines are being developed that contain an 
inducible KRASG12D driven by an acinar specific Ptf1a-cre. Exploring the role that Atf3 
plays in ADM development with a KRAS mutation will allow for a better understanding 
in how it may be increasing susceptibility to PDAC.  
Finally, as alluded to in the discussion, it is unknown whether Atf3 is implicated in 
increasing damage or repressing regeneration following chronic injury. Repeating the 
experiment and analyzing the mice at time points immediately following cessation of 
injury will allow for us to definitively conclude ATF3’s role in either promoting damage 
or blocking regeneration.  
In conclusion, this study identifies Atf3 as potential regulator of ADM. ATF3 may be 
driving this process through either affecting the acinar genetic program to promote 
progenitor and ductal cell formation, through increased EGFR signalling, or both (Figure 
4.1). While ATF3 is not necessary for cyst formation, as evident in primary acinar 
cultures, it is implicated in the ADM process since loss of Atf3 results in maintained 
mature acinar marker expression (amylase). To determine the role of ATF3 in driving the 
ADM process following chronic injury, and therefore potentially increasing susceptibility 
to PDAC, analyzing how loss of Atf3 reduces ADM, through either decreasing damage or 
increasing regenerative capacity, is necessary (Figure 4.1). Further studies to elucidate 
the mechanism of genetic regulations in the pancreas will provide insight as to how ATF3 
may be targeted for either diagnostic or therapeutic purposes.  
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Figure 4.1 ATF3 promotes acinar-to-duct cell metaplasia by affecting the acinar 
genetic program and inhibiting pancreatic regeneration following injury. When the 
pancreas is exposed to injury, it will attempt to regenerate and repopulate damaged acinar 
cells. However, ATF3 may be blocking this regenerative process and instead promote 
acinar-to-duct cell metaplasia (ADM) by affecting the acinar genetic program and 
increasing EGFR signalling. Regeneration may be inhibited by ATF3s effects on EGFR 
and Notch signalling, as well as inflammation.  
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Appendices  
 
 
Appendix 1. Representative analysis of cell thickness 
Representative analysis of cell thickness in reference to Figure 9. Using Image J 
software, 3 points around the cyst were measured across the length of the nuclei to 
determine the thickness of the cells composing the cyst. An average of 3 distinct points 
per cyst was recorded.  
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